MAP2K6
TYR version of PSPA with Y as phospho-acceptor
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O00165 | S153 | Sugiyama | HAX1 HS1BP1 | PDSHQPRIFGGVLESDARSEsPQPAPDWGsQRPFHRFDDVW |
| O14545 | S327 | Sugiyama | TRAFD1 FLN29 | DHQTSCNPSRALPsLNtGsssPRGVEEPDVIFQNFLQQAAS |
| O15264 | T180 | GPS6|SIGNOR|EPSD|PSP | MAPK13 PRKM13 SAPK4 | EDCELKILDFGLARHADAEMtGyVVtRWYRAPEVILSWMHY |
| O15264 | Y182 | SIGNOR|PSP | MAPK13 PRKM13 SAPK4 | CELKILDFGLARHADAEMtGyVVtRWYRAPEVILSWMHYNQ |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60716 | S252 | Sugiyama | CTNND1 KIAA0384 | sRVtRIEERyRPsMEGyRAPsRQDVyGPQPQVRVGGssVDL |
| P00558 | T168 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | EAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNLPQKAGGF |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P07195 | S320 | Sugiyama | LDHB | GLtsVINQKLKDDEVAQLKKsADtLWDIQKDLKDL______ |
| P07205 | T168 | Sugiyama | PGK2 PGKB | EAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNLPHKASGF |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P17812 | S575 | Sugiyama | CTPS1 CTPS | LQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD____ |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P23434 | Y139 | Sugiyama | GCSH | EVTEINEALAENPGLVNKSCyEDGWLIKMtLsNPsELDELM |
| P25398 | Y127 | Sugiyama | RPS12 | sCVVVKDYGKESQAKDVIEEyFKCKK_______________ |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P31943 | Y266 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | yNGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGstFQst |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P40818 | S719 | Sugiyama | USP8 KIAA0055 UBPY | KPQIPAERDREPSKLKRsyssPDItQAIQEEEKRKPTVtPT |
| P42166 | T160 | Sugiyama | TMPO LAP2 | KLYEKKLLKLREQGtEsRsstPLPtIsssAENtRQNGsNDs |
| P42167 | T160 | Sugiyama | TMPO LAP2 | KLYEKKLLKLREQGTESRsstPLPTISsSAENTRQNGSNDS |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P52564 | S207 | EPSD|PSP | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | INALGQVKMCDFGISGyLVDsVAKtIDAGCKPyMAPERINP |
| P52564 | S26 | Sugiyama | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | GKKRNPGLKIPKEAFEQPQtsstPPRDLDsKACISIGNQNF |
| P52564 | S27 | Sugiyama | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | KKRNPGLKIPKEAFEQPQtsstPPRDLDsKACISIGNQNFE |
| P52564 | T25 | Sugiyama | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | KGKKRNPGLKIPKEAFEQPQtsstPPRDLDsKACISIGNQN |
| P52564 | T28 | Sugiyama | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | KRNPGLKIPKEAFEQPQtsstPPRDLDsKACISIGNQNFEV |
| P52564 | Y219 | EPSD|PSP | MAP2K6 MEK6 MKK6 PRKMK6 SKK3 | GISGyLVDsVAKtIDAGCKPyMAPERINPELNQKGYSVKSD |
| P53778 | T183 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | MAPK12 ERK6 SAPK3 | EDCELKILDFGLARQADsEMtGyVVtRWYRAPEVILNWMRY |
| P53778 | Y185 | SIGNOR|ELM|iPTMNet|EPSD|PSP | MAPK12 ERK6 SAPK3 | CELKILDFGLARQADsEMtGyVVtRWYRAPEVILNWMRYTQ |
| P55795 | Y266 | Sugiyama | HNRNPH2 FTP3 HNRPH2 | YGGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGssFQst |
| P60174 | Y209 | Sugiyama | TPI1 TPI | LRGWLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDG |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P63220 | Y53 | Sugiyama | RPS21 | QMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRLA |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| Q00613 | S363 | Sugiyama | HSF1 HSTF1 | AsVTALtDARGHTDtEGRPPsPPPtstPEKCLsVACLDKNE |
| Q01518 | T165 | Sugiyama | CAP1 CAP | AMAPKPGPYVKEMNDAAMFytNRVLKEYKDVDKKHVDWVKA |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q12913 | S843 | Sugiyama | PTPRJ DEP1 | PNITSVSHNSVKVKFSGFEAsHGPIKAYAVILTTGEAGHPS |
| Q13247 | S303 | Sugiyama | SRSF6 SFRS6 SRP55 | ENGKGDIKsKSRsRsQsRsNsPLPVPPsKARsVsPPPKRAT |
| Q13283 | S232 | Sugiyama | G3BP1 G3BP | EEKPEPVLEETAPEDAQKsssPAPADIAQtVQEDLRtFsWA |
| Q14152 | S988 | Sugiyama | EIF3A EIF3S10 KIAA0139 | PRRGPEEDRFsRRGADDDRPsWRNTDDDRPPRRIADEDRGN |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q14765 | S721 | SIGNOR|iPTMNet|EPSD | STAT4 | ISTIRSDSTEPHsPSDLLPMsPSVYAVLRENLsPTTIETAM |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q15637 | S82 | Sugiyama | SF1 ZFM1 ZNF162 | TRKLRtGDLGIPPNPEDRsPsPEPIyNsEGKRLNTREFRTR |
| Q15759 | T180 | GPS6|EPSD | MAPK11 PRKM11 SAPK2 SAPK2B | EDCELRILDFGLARQADEEMtGyVAtRWYRAPEIMLNWMHY |
| Q15759 | Y182 | EPSD | MAPK11 PRKM11 SAPK2 SAPK2B | CELRILDFGLARQADEEMtGyVAtRWYRAPEIMLNWMHYNQ |
| Q16539 | T180 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | MAPK14 CSBP CSBP1 CSBP2 CSPB1 MXI2 SAPK2A | EDCELKILDFGLARHtDDEMtGyVAtRWYRAPEIMLNWMHY |
| Q16539 | Y182 | SIGNOR|iPTMNet|EPSD|PSP | MAPK14 CSBP CSBP1 CSBP2 CSPB1 MXI2 SAPK2A | CELKILDFGLARHtDDEMtGyVAtRWYRAPEIMLNWMHYNQ |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q6GYQ0 | T1002 | Sugiyama | RALGAPA1 GARNL1 KIAA0884 TULIP1 | TITGSESASPVHSPLGSRsQtPsPSTLNIDHMEQKDLQLDE |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q6UN15 | S492 | Sugiyama | FIP1L1 FIP1 RHE | DRDRDRERERTRERERERDHsPtPsVFNsDEERyRYREYAE |
| Q7L2J0 | S216 | Sugiyama | MEPCE BCDIN3 | NLNSLLDEEVSRtLNAEtPKssPLPAKGRDPVEILIPKDIt |
| Q7L2J0 | T213 | Sugiyama | MEPCE BCDIN3 | DPLNLNSLLDEEVSRtLNAEtPKssPLPAKGRDPVEILIPK |
| Q7Z2W4 | T273 | Sugiyama | ZC3HAV1 ZC3HDC2 PRO1677 | FFQGsQEFLASASAsAERsCtPsPDQIsHRAsLEDAPVDDL |
| Q8IWX8 | S817 | Sugiyama | CHERP DAN26 SCAF6 | QSRSRSKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDS |
| Q8IWX8 | T819 | Sugiyama | CHERP DAN26 SCAF6 | RSRSKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDSRL |
| Q8N684 | T203 | Sugiyama | CPSF7 | GGIPPRAHsRDssDsADGRAtPsENLVPSSARVDKPPSVLP |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q96CT7 | Y38 | Sugiyama | CCDC124 | RRAEAKAAADAKKQKELEDAyWKDDDKHVMRKEQRKEEKEK |
| Q96MU7 | S308 | Sugiyama | YTHDC1 KIAA1966 YT521 | GSGTDGsDEKKKERKRARGIsPIVFDRsGssAsESYAGsEK |
| Q96S44 | T8 | Sugiyama | TP53RK C20orf64 PRPK | _____________MAAARAttPADGEEPAPEAEALAAARER |
| Q99759 | S337 | Sugiyama | MAP3K3 MAPKKK3 MEKK3 | tNGENMGLAVQYLDPRGRLRsADsENALsVQERNVPTKsPs |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9H7N4 | S498 | Sugiyama | SCAF1 SFRS19 SRA1 | GGLDLRRKILTQRRERyRQRsPsPAPAPAPAAAAGPPTRKK |
| Q9H7N4 | S500 | Sugiyama | SCAF1 SFRS19 SRA1 | LDLRRKILTQRRERyRQRsPsPAPAPAPAAAAGPPTRKKSR |
| Q9NQU5 | T564 | GPS6|ELM|iPTMNet|EPSD | PAK6 PAK5 | DFGFCAQISKDVPKRKsLVGtPyWMAPEVISRSLYATEVDI |
| Q9NQU5 | Y566 | SIGNOR|ELM|iPTMNet|EPSD|PSP | PAK6 PAK5 | GFCAQISKDVPKRKsLVGtPyWMAPEVISRSLYATEVDIWS |
| Q9NWB6 | S77 | Sugiyama | ARGLU1 | RsRstNTAVSRRERDRERAssPPDRIDIFGRTVSKRSSLDE |
| Q9ULV5 | T471 | SIGNOR|EPSD|PSP | HSF4 | LLLDVQAALGGPALGLPGALtIYSTPESRTASYLGPEASPS |
| Q9UQ35 | S1103 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | sPsLQSKSQTsPKGGRsRsssPVtELAsRsPIRQDRGEFsA |
| Q9UQ35 | S2046 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | IRRRsRsRtPLLPRKRsRsRsPLAIRRRSRSRTPRTARGKR |
| Q9UQ35 | S2132 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | SRMsCFsRPsMsPtPLDRCRsPGMLEPLGssRtPMsVLQQA |
| Q9Y2V2 | S30 | Sugiyama | CARHSP1 | QPPtHQAsVGLLDtPRsRERsPsPLRGNVVPsPLPtRRtRt |
| Q9Y2V2 | S32 | Sugiyama | CARHSP1 | PtHQAsVGLLDtPRsRERsPsPLRGNVVPsPLPtRRtRtFs |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.538615e-09 | 8.813 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.289584e-08 | 7.640 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 4.614512e-08 | 7.336 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.719480e-07 | 6.566 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.606999e-07 | 6.337 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 7.428548e-07 | 6.129 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 8.712242e-06 | 5.060 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 2.327109e-05 | 4.633 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.458575e-04 | 3.836 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 6.560186e-04 | 3.183 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.375265e-04 | 3.196 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 8.198915e-04 | 3.086 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.105497e-03 | 2.677 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.112253e-03 | 2.675 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.105497e-03 | 2.677 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.256210e-03 | 2.487 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.916367e-03 | 2.407 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.397924e-03 | 2.357 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 4.635586e-03 | 2.334 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 5.410963e-03 | 2.267 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 5.246573e-03 | 2.280 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 6.919446e-03 | 2.160 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.650615e-02 | 1.782 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.650615e-02 | 1.782 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.650615e-02 | 1.782 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.650615e-02 | 1.782 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.650615e-02 | 1.782 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.650615e-02 | 1.782 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.650615e-02 | 1.782 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.737861e-02 | 1.760 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.605809e-02 | 1.794 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.275606e-02 | 1.894 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.604669e-02 | 1.795 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.476094e-02 | 1.831 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.745152e-02 | 1.758 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.960101e-02 | 1.708 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.164301e-02 | 1.665 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.164301e-02 | 1.665 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.465753e-02 | 1.608 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.315129e-02 | 1.635 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.328218e-02 | 1.633 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.629326e-02 | 1.580 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.644486e-02 | 1.578 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.523609e-02 | 1.598 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.792537e-02 | 1.554 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.792537e-02 | 1.554 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.563093e-02 | 1.591 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 3.015461e-02 | 1.521 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.130802e-02 | 1.504 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.130802e-02 | 1.504 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.305704e-02 | 1.481 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.305704e-02 | 1.481 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.659790e-02 | 1.247 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.441941e-02 | 1.191 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.441941e-02 | 1.191 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 6.441941e-02 | 1.191 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 6.441941e-02 | 1.191 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 7.217655e-02 | 1.142 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 7.217655e-02 | 1.142 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 7.217655e-02 | 1.142 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 7.217655e-02 | 1.142 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 7.986985e-02 | 1.098 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 8.749984e-02 | 1.058 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.025719e-01 | 0.989 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 1.247179e-01 | 0.904 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.247179e-01 | 0.904 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.319787e-01 | 0.879 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 1.391797e-01 | 0.856 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.463214e-01 | 0.835 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.463214e-01 | 0.835 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.534043e-01 | 0.814 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.673956e-01 | 0.776 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.743049e-01 | 0.759 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 5.894760e-02 | 1.230 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 5.894760e-02 | 1.230 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.811573e-01 | 0.742 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.811573e-01 | 0.742 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.879533e-01 | 0.726 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.879533e-01 | 0.726 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.879533e-01 | 0.726 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.879533e-01 | 0.726 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 1.946933e-01 | 0.711 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 7.498891e-02 | 1.125 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.013777e-01 | 0.696 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.145819e-01 | 0.668 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.145819e-01 | 0.668 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 8.970336e-02 | 1.047 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 9.223329e-02 | 1.035 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 9.223329e-02 | 1.035 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.275693e-01 | 0.643 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.466518e-01 | 0.608 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.466518e-01 | 0.608 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.529081e-01 | 0.597 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 1.323974e-01 | 0.878 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.652663e-01 | 0.576 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.894760e-02 | 1.230 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 2.529081e-01 | 0.597 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 2.591128e-01 | 0.587 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.894760e-02 | 1.230 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.879533e-01 | 0.726 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.100150e-01 | 0.959 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.676583e-02 | 1.246 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 2.080071e-01 | 0.682 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 2.893774e-01 | 0.539 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.871149e-02 | 1.312 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 2.403435e-01 | 0.619 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 6.068111e-02 | 1.217 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.875861e-01 | 0.727 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.879533e-01 | 0.726 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.494149e-01 | 0.826 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.319787e-01 | 0.879 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 2.466518e-01 | 0.608 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.774217e-01 | 0.557 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.894760e-02 | 1.230 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.514253e-01 | 0.600 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.514253e-01 | 0.600 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.463214e-01 | 0.835 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.774217e-01 | 0.557 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.834243e-01 | 0.548 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.339828e-01 | 0.631 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 6.441941e-02 | 1.191 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 4.628907e-02 | 1.335 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.089618e-01 | 0.680 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.774217e-01 | 0.557 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 6.115806e-02 | 1.214 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.946933e-01 | 0.711 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.408497e-01 | 0.851 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.025554e-01 | 0.989 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 2.591128e-01 | 0.587 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 1.158762e-01 | 0.936 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.871149e-02 | 1.312 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 9.506702e-02 | 1.022 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.173969e-01 | 0.930 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.173969e-01 | 0.930 | 0 | 0 |
| PKA activation | R-HSA-163615 | 1.743049e-01 | 0.759 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 1.743049e-01 | 0.759 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 1.743049e-01 | 0.759 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 1.811573e-01 | 0.742 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.080071e-01 | 0.682 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.893774e-01 | 0.539 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 2.893774e-01 | 0.539 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 2.339828e-01 | 0.631 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.080071e-01 | 0.682 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.591128e-01 | 0.587 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.266415e-01 | 0.897 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.743049e-01 | 0.759 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.408497e-01 | 0.851 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 2.834243e-01 | 0.548 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 1.879533e-01 | 0.726 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.025719e-01 | 0.989 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 4.234980e-02 | 1.373 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.078308e-01 | 0.967 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.713692e-01 | 0.566 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.713223e-01 | 0.766 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.894760e-02 | 1.230 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.894760e-02 | 1.230 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.466518e-01 | 0.608 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.529081e-01 | 0.597 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.893774e-01 | 0.539 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 1.173969e-01 | 0.930 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 2.275693e-01 | 0.643 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 2.529081e-01 | 0.597 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 2.774217e-01 | 0.557 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.893774e-01 | 0.539 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.668421e-01 | 0.778 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.529081e-01 | 0.597 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 7.980155e-02 | 1.098 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 8.224325e-02 | 1.085 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 9.506702e-02 | 1.022 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.952814e-01 | 0.530 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.463214e-01 | 0.835 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.241968e-02 | 1.084 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.958110e-02 | 1.305 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.078308e-01 | 0.967 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.056609e-01 | 0.976 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.441941e-02 | 1.191 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 8.749984e-02 | 1.058 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 1.100150e-01 | 0.959 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.463214e-01 | 0.835 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.534043e-01 | 0.814 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 1.534043e-01 | 0.814 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.211024e-01 | 0.655 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.774217e-01 | 0.557 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.039882e-02 | 1.298 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.774217e-01 | 0.557 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.104954e-01 | 0.957 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.296069e-01 | 0.887 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.110122e-01 | 0.955 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.154222e-01 | 0.667 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.154222e-01 | 0.667 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.441941e-02 | 1.191 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.247179e-01 | 0.904 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.247179e-01 | 0.904 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.247179e-01 | 0.904 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.189906e-02 | 1.143 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 3.773863e-02 | 1.423 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.068836e-01 | 0.971 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.566252e-02 | 1.183 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.108938e-01 | 0.676 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 3.011367e-01 | 0.521 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 1.247179e-01 | 0.904 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.391797e-01 | 0.856 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.604289e-01 | 0.795 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.339828e-01 | 0.631 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 2.834243e-01 | 0.548 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 3.011367e-01 | 0.521 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 2.086651e-01 | 0.681 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 2.539546e-01 | 0.595 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.319787e-01 | 0.879 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.463214e-01 | 0.835 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.025554e-01 | 0.989 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.905794e-01 | 0.720 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 8.749984e-02 | 1.058 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 1.811573e-01 | 0.742 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.811573e-01 | 0.742 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 1.879533e-01 | 0.726 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.668421e-01 | 0.778 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.211024e-01 | 0.655 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.211024e-01 | 0.655 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.713692e-01 | 0.566 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.035792e-01 | 0.985 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.946933e-01 | 0.711 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.946933e-01 | 0.711 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.659790e-02 | 1.247 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.391797e-01 | 0.856 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 1.811573e-01 | 0.742 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.080071e-01 | 0.682 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 2.275693e-01 | 0.643 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 2.339828e-01 | 0.631 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.403435e-01 | 0.619 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.011367e-01 | 0.521 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 2.275693e-01 | 0.643 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 3.011367e-01 | 0.521 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.269209e-01 | 0.644 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.962938e-02 | 1.099 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.875861e-01 | 0.727 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 1.391797e-01 | 0.856 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.713692e-01 | 0.566 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.203480e-02 | 1.207 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.198030e-02 | 1.208 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.340255e-02 | 1.198 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.534043e-01 | 0.814 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.970446e-01 | 0.705 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.494149e-01 | 0.826 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.391797e-01 | 0.856 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 1.879533e-01 | 0.726 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 1.051840e-01 | 0.978 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 1.580824e-01 | 0.801 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.668421e-01 | 0.778 | 1 | 1 |
| Cell Cycle | R-HSA-1640170 | 2.621307e-01 | 0.581 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 6.418203e-02 | 1.193 | 1 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 5.461335e-02 | 1.263 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.339828e-01 | 0.631 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.743049e-01 | 0.759 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.211024e-01 | 0.655 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.733600e-01 | 0.761 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.589541e-01 | 0.587 | 1 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.422212e-01 | 0.616 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 2.652663e-01 | 0.576 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 5.255370e-02 | 1.279 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.483558e-01 | 0.605 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.477874e-01 | 0.606 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 1.247179e-01 | 0.904 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 2.893774e-01 | 0.539 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 3.011367e-01 | 0.521 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.857282e-01 | 0.731 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 2.514253e-01 | 0.600 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 8.342176e-02 | 1.079 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.566357e-01 | 0.591 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.080071e-01 | 0.682 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.774217e-01 | 0.557 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 6.140476e-02 | 1.212 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.733600e-01 | 0.761 | 1 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 4.833807e-02 | 1.316 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 6.115806e-02 | 1.214 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 2.275693e-01 | 0.643 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 3.011367e-01 | 0.521 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.821449e-01 | 0.550 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 1.463214e-01 | 0.835 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 2.652663e-01 | 0.576 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.952814e-01 | 0.530 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 1.436928e-01 | 0.843 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.673956e-01 | 0.776 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.673956e-01 | 0.776 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 3.011367e-01 | 0.521 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.416699e-01 | 0.849 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 2.211024e-01 | 0.655 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.319787e-01 | 0.879 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.952814e-01 | 0.530 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.011367e-01 | 0.521 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.668421e-01 | 0.778 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.575673e-01 | 0.589 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.857282e-01 | 0.731 | 1 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 3.011367e-01 | 0.521 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 2.353063e-01 | 0.628 | 1 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.011367e-01 | 0.521 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.121232e-01 | 0.950 | 1 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.211024e-01 | 0.655 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.240690e-01 | 0.906 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.051292e-01 | 0.688 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.551825e-01 | 0.809 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.905794e-01 | 0.720 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.036020e-01 | 0.518 | 1 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.036020e-01 | 0.518 | 1 | 0 |
| Mitotic Prophase | R-HSA-68875 | 3.066596e-01 | 0.513 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.069437e-01 | 0.513 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.127029e-01 | 0.505 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.127029e-01 | 0.505 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.127673e-01 | 0.505 | 1 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.127673e-01 | 0.505 | 1 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.134645e-01 | 0.504 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.157327e-01 | 0.501 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.158170e-01 | 0.501 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.158170e-01 | 0.501 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.184145e-01 | 0.497 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.184145e-01 | 0.497 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.184145e-01 | 0.497 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.184145e-01 | 0.497 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.240790e-01 | 0.489 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.240790e-01 | 0.489 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 3.279849e-01 | 0.484 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.296968e-01 | 0.482 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.296968e-01 | 0.482 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.296968e-01 | 0.482 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.310183e-01 | 0.480 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 3.310183e-01 | 0.480 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 3.352683e-01 | 0.475 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 3.352683e-01 | 0.475 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 3.352683e-01 | 0.475 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.352683e-01 | 0.475 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.352683e-01 | 0.475 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.352683e-01 | 0.475 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 3.352683e-01 | 0.475 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 3.352683e-01 | 0.475 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 3.352683e-01 | 0.475 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.352683e-01 | 0.475 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.407938e-01 | 0.468 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 3.407938e-01 | 0.468 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.407938e-01 | 0.468 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.407938e-01 | 0.468 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 3.462737e-01 | 0.461 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.462737e-01 | 0.461 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.462737e-01 | 0.461 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.462737e-01 | 0.461 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.517083e-01 | 0.454 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 3.517083e-01 | 0.454 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.517083e-01 | 0.454 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 3.521399e-01 | 0.453 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 3.555588e-01 | 0.449 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 3.570982e-01 | 0.447 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.570982e-01 | 0.447 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 3.570982e-01 | 0.447 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.570982e-01 | 0.447 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.570982e-01 | 0.447 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 3.570982e-01 | 0.447 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.570982e-01 | 0.447 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.570982e-01 | 0.447 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.624435e-01 | 0.441 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.624435e-01 | 0.441 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.624435e-01 | 0.441 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.624435e-01 | 0.441 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.624435e-01 | 0.441 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 3.624435e-01 | 0.441 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 3.624435e-01 | 0.441 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 3.624435e-01 | 0.441 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.641092e-01 | 0.439 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 3.670889e-01 | 0.435 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 3.677447e-01 | 0.434 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.677447e-01 | 0.434 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 3.730022e-01 | 0.428 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.782163e-01 | 0.422 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.782163e-01 | 0.422 | 0 | 0 |
| Immune System | R-HSA-168256 | 3.783942e-01 | 0.422 | 1 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 3.789533e-01 | 0.421 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 3.833874e-01 | 0.416 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.848514e-01 | 0.415 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 3.885157e-01 | 0.411 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 3.885157e-01 | 0.411 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 3.885157e-01 | 0.411 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 3.885157e-01 | 0.411 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.936018e-01 | 0.405 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.936018e-01 | 0.405 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 3.936018e-01 | 0.405 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.960413e-01 | 0.402 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 3.986458e-01 | 0.399 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 3.994904e-01 | 0.398 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.023991e-01 | 0.395 | 1 | 0 |
| S Phase | R-HSA-69242 | 4.023991e-01 | 0.395 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 4.036482e-01 | 0.394 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 4.081969e-01 | 0.389 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.135294e-01 | 0.383 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.135294e-01 | 0.383 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 4.135294e-01 | 0.383 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.135294e-01 | 0.383 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 4.135294e-01 | 0.383 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.184089e-01 | 0.378 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.232481e-01 | 0.373 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.232481e-01 | 0.373 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 4.280473e-01 | 0.369 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 4.280473e-01 | 0.369 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 4.280473e-01 | 0.369 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.282723e-01 | 0.368 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.328069e-01 | 0.364 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.328069e-01 | 0.364 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.328069e-01 | 0.364 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.328069e-01 | 0.364 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.328069e-01 | 0.364 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.328069e-01 | 0.364 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.342910e-01 | 0.362 | 1 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 4.375271e-01 | 0.359 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 4.375271e-01 | 0.359 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 4.375271e-01 | 0.359 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.375271e-01 | 0.359 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.422084e-01 | 0.354 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.434562e-01 | 0.353 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.468510e-01 | 0.350 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.468510e-01 | 0.350 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.560215e-01 | 0.341 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 4.586240e-01 | 0.339 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 4.586240e-01 | 0.339 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.618227e-01 | 0.336 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.650410e-01 | 0.333 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 4.650410e-01 | 0.333 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 4.650410e-01 | 0.333 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.700546e-01 | 0.328 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 4.737135e-01 | 0.324 | 1 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 4.754893e-01 | 0.323 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 4.754893e-01 | 0.323 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.754893e-01 | 0.323 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.781942e-01 | 0.320 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 4.782928e-01 | 0.320 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 4.782928e-01 | 0.320 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.782928e-01 | 0.320 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.782928e-01 | 0.320 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 4.808906e-01 | 0.318 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 4.826372e-01 | 0.316 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 4.826372e-01 | 0.316 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 4.869457e-01 | 0.313 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 4.869457e-01 | 0.313 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.884247e-01 | 0.311 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 4.912186e-01 | 0.309 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.954562e-01 | 0.305 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.954562e-01 | 0.305 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.996587e-01 | 0.301 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.996587e-01 | 0.301 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 5.038265e-01 | 0.298 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.038265e-01 | 0.298 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.038265e-01 | 0.298 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 5.072827e-01 | 0.295 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 5.120590e-01 | 0.291 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 5.120590e-01 | 0.291 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 5.120590e-01 | 0.291 | 0 | 0 |
| Disease | R-HSA-1643685 | 5.127390e-01 | 0.290 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.201560e-01 | 0.284 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.228549e-01 | 0.282 | 1 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 5.241543e-01 | 0.281 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 5.241543e-01 | 0.281 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.241543e-01 | 0.281 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 5.241543e-01 | 0.281 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 5.320519e-01 | 0.274 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 5.355001e-01 | 0.271 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.398195e-01 | 0.268 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 5.398195e-01 | 0.268 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 5.398195e-01 | 0.268 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.455359e-01 | 0.263 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 5.512315e-01 | 0.259 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 5.528181e-01 | 0.257 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.549727e-01 | 0.256 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.586830e-01 | 0.253 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 5.611727e-01 | 0.251 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.623626e-01 | 0.250 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 5.623626e-01 | 0.250 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 5.641244e-01 | 0.249 | 1 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 5.660117e-01 | 0.247 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.732195e-01 | 0.242 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 5.740706e-01 | 0.241 | 1 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.767671e-01 | 0.239 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 5.767788e-01 | 0.239 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 5.767788e-01 | 0.239 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 5.791105e-01 | 0.237 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 5.803086e-01 | 0.236 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.838091e-01 | 0.234 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 5.907236e-01 | 0.229 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.907236e-01 | 0.229 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.907236e-01 | 0.229 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.914652e-01 | 0.228 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 5.975240e-01 | 0.224 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 5.975240e-01 | 0.224 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.975240e-01 | 0.224 | 1 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.975240e-01 | 0.224 | 1 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.975240e-01 | 0.224 | 1 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 6.008820e-01 | 0.221 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.042122e-01 | 0.219 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 6.042122e-01 | 0.219 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.075148e-01 | 0.216 | 1 | 1 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.107901e-01 | 0.214 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.107901e-01 | 0.214 | 1 | 1 |
| HIV Infection | R-HSA-162906 | 6.109265e-01 | 0.214 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.131283e-01 | 0.212 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 6.172595e-01 | 0.210 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.203970e-01 | 0.207 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 6.236221e-01 | 0.205 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.236221e-01 | 0.205 | 1 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.273238e-01 | 0.203 | 1 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.298798e-01 | 0.201 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.298798e-01 | 0.201 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 6.304033e-01 | 0.200 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 6.325204e-01 | 0.199 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 6.329697e-01 | 0.199 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.329697e-01 | 0.199 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.329697e-01 | 0.199 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.329697e-01 | 0.199 | 1 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 6.360341e-01 | 0.197 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.360341e-01 | 0.197 | 1 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 6.390731e-01 | 0.194 | 1 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 6.390731e-01 | 0.194 | 1 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 6.450757e-01 | 0.190 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.480398e-01 | 0.188 | 1 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.509792e-01 | 0.186 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 6.538943e-01 | 0.184 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.545842e-01 | 0.184 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 6.562351e-01 | 0.183 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.567853e-01 | 0.183 | 1 | 0 |
| HCMV Infection | R-HSA-9609646 | 6.591928e-01 | 0.181 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 6.596523e-01 | 0.181 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 6.596523e-01 | 0.181 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 6.596523e-01 | 0.181 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 6.624955e-01 | 0.179 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 6.624955e-01 | 0.179 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 6.653151e-01 | 0.177 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.653151e-01 | 0.177 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 6.681113e-01 | 0.175 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.708844e-01 | 0.173 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 6.748298e-01 | 0.171 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.763617e-01 | 0.170 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 6.787598e-01 | 0.168 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 6.896623e-01 | 0.161 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 6.896623e-01 | 0.161 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 6.896623e-01 | 0.161 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 6.896623e-01 | 0.161 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.935585e-01 | 0.159 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 6.973807e-01 | 0.157 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 7.049086e-01 | 0.152 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.073763e-01 | 0.150 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.098236e-01 | 0.149 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.098236e-01 | 0.149 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.182868e-01 | 0.144 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.217585e-01 | 0.142 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 7.235476e-01 | 0.141 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.263949e-01 | 0.139 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 7.300151e-01 | 0.137 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.309546e-01 | 0.136 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.309546e-01 | 0.136 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.309546e-01 | 0.136 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.376531e-01 | 0.132 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 7.413303e-01 | 0.130 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 7.420265e-01 | 0.130 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 7.463276e-01 | 0.127 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 7.484514e-01 | 0.126 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 7.505575e-01 | 0.125 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.526461e-01 | 0.123 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.567714e-01 | 0.121 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.588083e-01 | 0.120 | 1 | 0 |
| DNA Replication | R-HSA-69306 | 7.608284e-01 | 0.119 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 7.608284e-01 | 0.119 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 7.628316e-01 | 0.118 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 7.648182e-01 | 0.116 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 7.648182e-01 | 0.116 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 7.687420e-01 | 0.114 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 7.706794e-01 | 0.113 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 7.763601e-01 | 0.110 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 7.771136e-01 | 0.110 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 7.819703e-01 | 0.107 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 7.874071e-01 | 0.104 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 7.944473e-01 | 0.100 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 7.961709e-01 | 0.099 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 8.094531e-01 | 0.092 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.110517e-01 | 0.091 | 1 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.145570e-01 | 0.089 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 8.233709e-01 | 0.084 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.263240e-01 | 0.083 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 8.306621e-01 | 0.081 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.430413e-01 | 0.074 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 8.443601e-01 | 0.073 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 8.588996e-01 | 0.066 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 8.674272e-01 | 0.062 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 8.760929e-01 | 0.057 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 8.791955e-01 | 0.056 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 8.870973e-01 | 0.052 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 8.935892e-01 | 0.049 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.247067e-01 | 0.034 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 9.283194e-01 | 0.032 | 1 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.469527e-01 | 0.024 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 9.513393e-01 | 0.022 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.520799e-01 | 0.021 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.606062e-01 | 0.017 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 9.626543e-01 | 0.017 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.729416e-01 | 0.012 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 9.761853e-01 | 0.010 | 1 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.761995e-01 | 0.010 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.771965e-01 | 0.010 | 0 | 0 |
| Translation | R-HSA-72766 | 9.775836e-01 | 0.010 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.820600e-01 | 0.008 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.955983e-01 | 0.002 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.975013e-01 | 0.001 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.988687e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.994540e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.997719e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999721e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 1.000000e+00 | 0.000 | 1 | 1 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.000000e+00 | 0.000 | 1 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.000000e+00 | 0.000 | 1 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.000000e+00 | 0.000 | 1 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 1.000000e+00 | 0.000 | 1 | 1 |
| Myogenesis | R-HSA-525793 | 1.000000e+00 | 0.000 | 1 | 1 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.000000e+00 | 0.000 | 1 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.221245e-15 | 14.913 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.287059e-14 | 13.641 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 5.484502e-14 | 13.261 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.117506e-13 | 12.506 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.109446e-12 | 11.955 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.251444e-12 | 11.204 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.629266e-09 | 8.580 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.765223e-09 | 8.424 | 1 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.150604e-09 | 8.288 | 1 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 7.391992e-09 | 8.131 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.138978e-08 | 7.943 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.138978e-08 | 7.943 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.232023e-08 | 7.909 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.310485e-08 | 7.365 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.649630e-08 | 7.248 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 9.261539e-08 | 7.033 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.123209e-07 | 6.950 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.187443e-07 | 6.925 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.326211e-07 | 6.877 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.670574e-07 | 6.777 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.243012e-07 | 6.649 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.394032e-07 | 6.621 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 3.441451e-07 | 6.463 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.044119e-07 | 6.393 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.936705e-07 | 6.405 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.926600e-07 | 6.406 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.409001e-07 | 6.356 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.925764e-07 | 6.308 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.925764e-07 | 6.308 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 6.969921e-07 | 6.157 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 7.523103e-07 | 6.124 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.217878e-07 | 6.142 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.304264e-07 | 6.081 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 9.286230e-07 | 6.032 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 9.742708e-07 | 6.011 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.156698e-06 | 5.937 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.445116e-06 | 5.840 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.679189e-06 | 5.775 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.201699e-06 | 5.657 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.754049e-06 | 5.560 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.068031e-06 | 5.513 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.297705e-06 | 5.482 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.541137e-06 | 5.451 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 4.762125e-06 | 5.322 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 5.135799e-06 | 5.289 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 6.753280e-06 | 5.170 | 1 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 7.215240e-06 | 5.142 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 7.751213e-06 | 5.111 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.096079e-05 | 4.960 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.298338e-05 | 4.887 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.311056e-05 | 4.882 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.811340e-05 | 4.742 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.844205e-05 | 4.734 | 1 | 0 |
| Cell junction organization | R-HSA-446728 | 1.918472e-05 | 4.717 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.475682e-05 | 4.606 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.079832e-05 | 4.511 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 4.096198e-05 | 4.388 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 4.096198e-05 | 4.388 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 4.022696e-05 | 4.395 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.370759e-05 | 4.359 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.511185e-05 | 4.346 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 5.274875e-05 | 4.278 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 5.351983e-05 | 4.271 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 5.613653e-05 | 4.251 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.063529e-05 | 4.217 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 6.292757e-05 | 4.201 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 6.329550e-05 | 4.199 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 6.537357e-05 | 4.185 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 7.741905e-05 | 4.111 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 7.860324e-05 | 4.105 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 8.093857e-05 | 4.092 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 8.374802e-05 | 4.077 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 9.877251e-05 | 4.005 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.002106e-04 | 3.999 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.171732e-04 | 3.931 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.211068e-04 | 3.917 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.331514e-04 | 3.876 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.349449e-04 | 3.870 | 1 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.496040e-04 | 3.825 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.583029e-04 | 3.801 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.583029e-04 | 3.801 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.583029e-04 | 3.801 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.771793e-04 | 3.752 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.771793e-04 | 3.752 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.811433e-04 | 3.742 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.833295e-04 | 3.737 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.928032e-04 | 3.715 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.091206e-04 | 3.680 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.995144e-04 | 3.700 | 1 | 1 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.091206e-04 | 3.680 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.253253e-04 | 3.647 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.329589e-04 | 3.633 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.382208e-04 | 3.623 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 2.253253e-04 | 3.647 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.775632e-04 | 3.557 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.993526e-04 | 3.524 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.234156e-04 | 3.490 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.253507e-04 | 3.488 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.402534e-04 | 3.468 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.456479e-04 | 3.461 | 0 | 0 |
| S Phase | R-HSA-69242 | 3.857279e-04 | 3.414 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.951889e-04 | 3.403 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 4.358585e-04 | 3.361 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.369780e-04 | 3.360 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 4.553350e-04 | 3.342 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.657020e-04 | 3.332 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 4.853498e-04 | 3.314 | 1 | 1 |
| Adherens junctions interactions | R-HSA-418990 | 4.729693e-04 | 3.325 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.565948e-04 | 3.340 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.898670e-04 | 3.310 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 4.920636e-04 | 3.308 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.043558e-04 | 3.297 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.689674e-04 | 3.245 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 5.762624e-04 | 3.239 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 6.802739e-04 | 3.167 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.530819e-04 | 3.185 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 6.833965e-04 | 3.165 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.427564e-04 | 3.192 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 6.964286e-04 | 3.157 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 7.271595e-04 | 3.138 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 7.513240e-04 | 3.124 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 7.891373e-04 | 3.103 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.008209e-04 | 3.096 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 8.468265e-04 | 3.072 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.197378e-04 | 3.086 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 8.468265e-04 | 3.072 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.891373e-04 | 3.103 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 8.000293e-04 | 3.097 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 8.485687e-04 | 3.071 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 9.183528e-04 | 3.037 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 9.499980e-04 | 3.022 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.038042e-03 | 2.984 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.023064e-03 | 2.990 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.014661e-03 | 2.994 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 9.767657e-04 | 3.010 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 9.946356e-04 | 3.002 | 1 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.014661e-03 | 2.994 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 9.583241e-04 | 3.018 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.143591e-03 | 2.942 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.145081e-03 | 2.941 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.210689e-03 | 2.917 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.329324e-03 | 2.876 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.367499e-03 | 2.864 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.367499e-03 | 2.864 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.313684e-03 | 2.882 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.379666e-03 | 2.860 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.431143e-03 | 2.844 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.431143e-03 | 2.844 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.378722e-03 | 2.861 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.333111e-03 | 2.875 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.333111e-03 | 2.875 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.431143e-03 | 2.844 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.431143e-03 | 2.844 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.329324e-03 | 2.876 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.438717e-03 | 2.842 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.531863e-03 | 2.815 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.679631e-03 | 2.775 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.688982e-03 | 2.772 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.690514e-03 | 2.772 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.722872e-03 | 2.764 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.749340e-03 | 2.757 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.783084e-03 | 2.749 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.786710e-03 | 2.748 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.822444e-03 | 2.739 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.822444e-03 | 2.739 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.000078e-03 | 2.699 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.960343e-03 | 2.708 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.949126e-03 | 2.710 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.022873e-03 | 2.694 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.062551e-03 | 2.686 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.080085e-03 | 2.682 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 2.080085e-03 | 2.682 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.226350e-03 | 2.652 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.294144e-03 | 2.639 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.377064e-03 | 2.624 | 1 | 1 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.394607e-03 | 2.621 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.398353e-03 | 2.620 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 2.470816e-03 | 2.607 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.485039e-03 | 2.605 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.448193e-03 | 2.611 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.463559e-03 | 2.608 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.679908e-03 | 2.572 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.485039e-03 | 2.605 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.427640e-03 | 2.615 | 1 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.677443e-03 | 2.572 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.679908e-03 | 2.572 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.637168e-03 | 2.579 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 2.537355e-03 | 2.596 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.769847e-03 | 2.558 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.788008e-03 | 2.555 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.788008e-03 | 2.555 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.788008e-03 | 2.555 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.788008e-03 | 2.555 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.788008e-03 | 2.555 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.901508e-03 | 2.537 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.924918e-03 | 2.534 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.924918e-03 | 2.534 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.934342e-03 | 2.532 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.934342e-03 | 2.532 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.962705e-03 | 2.528 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.025762e-03 | 2.519 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.113756e-03 | 2.507 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.494441e-03 | 2.457 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.193188e-03 | 2.496 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.381424e-03 | 2.471 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.453804e-03 | 2.462 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 3.381424e-03 | 2.471 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.252206e-03 | 2.488 | 1 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 3.113756e-03 | 2.507 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 3.133908e-03 | 2.504 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.241511e-03 | 2.489 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.507859e-03 | 2.455 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 3.615769e-03 | 2.442 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.692722e-03 | 2.433 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 3.692722e-03 | 2.433 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.785968e-03 | 2.422 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 3.826355e-03 | 2.417 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 4.119071e-03 | 2.385 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 4.119071e-03 | 2.385 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 4.123994e-03 | 2.385 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 4.123994e-03 | 2.385 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 4.146502e-03 | 2.382 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.177334e-03 | 2.379 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.195936e-03 | 2.377 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.265865e-03 | 2.370 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.265865e-03 | 2.370 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.265865e-03 | 2.370 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.265865e-03 | 2.370 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 4.291920e-03 | 2.367 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 4.363216e-03 | 2.360 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.729612e-03 | 2.325 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 4.996542e-03 | 2.301 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 4.996542e-03 | 2.301 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 4.996542e-03 | 2.301 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 4.708442e-03 | 2.327 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 4.996542e-03 | 2.301 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.705509e-03 | 2.327 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 4.751635e-03 | 2.323 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.705509e-03 | 2.327 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.705509e-03 | 2.327 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 4.900673e-03 | 2.310 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.803408e-03 | 2.318 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 5.147986e-03 | 2.288 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 5.150794e-03 | 2.288 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.332578e-03 | 2.273 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.488240e-03 | 2.261 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.760512e-03 | 2.240 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 5.887414e-03 | 2.230 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.900981e-03 | 2.229 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 5.980111e-03 | 2.223 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 6.061970e-03 | 2.217 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 6.193150e-03 | 2.208 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 6.193150e-03 | 2.208 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 6.193150e-03 | 2.208 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 6.193150e-03 | 2.208 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 6.356316e-03 | 2.197 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 6.330739e-03 | 2.199 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 7.118940e-03 | 2.148 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 6.506860e-03 | 2.187 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.506860e-03 | 2.187 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 7.039218e-03 | 2.152 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 6.899752e-03 | 2.161 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.331744e-03 | 2.198 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.372393e-03 | 2.196 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.510348e-03 | 2.186 | 1 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.195019e-03 | 2.208 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.911289e-03 | 2.160 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.331744e-03 | 2.198 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 6.356316e-03 | 2.197 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.793373e-03 | 2.168 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 7.162104e-03 | 2.145 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 7.197859e-03 | 2.143 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 7.210524e-03 | 2.142 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.210524e-03 | 2.142 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.260436e-03 | 2.139 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 7.260436e-03 | 2.139 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 7.317055e-03 | 2.136 | 1 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 7.485617e-03 | 2.126 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 7.536556e-03 | 2.123 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 7.536556e-03 | 2.123 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 7.855438e-03 | 2.105 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 8.137471e-03 | 2.090 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 8.173952e-03 | 2.088 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 8.211823e-03 | 2.086 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.225056e-03 | 2.085 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 8.225056e-03 | 2.085 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 8.231821e-03 | 2.085 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 8.231821e-03 | 2.085 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.265801e-03 | 2.083 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 8.457816e-03 | 2.073 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.562234e-03 | 2.067 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.562234e-03 | 2.067 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.061391e-03 | 2.043 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 9.081998e-03 | 2.042 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 9.129446e-03 | 2.040 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 9.163480e-03 | 2.038 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.311665e-03 | 2.031 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 9.691056e-03 | 2.014 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.758653e-03 | 2.011 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 9.856606e-03 | 2.006 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 9.856606e-03 | 2.006 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 9.856606e-03 | 2.006 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.002132e-02 | 1.999 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.005600e-02 | 1.998 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.007696e-02 | 1.997 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 1.028391e-02 | 1.988 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.236061e-02 | 1.908 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.247812e-02 | 1.904 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.247812e-02 | 1.904 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.217042e-02 | 1.915 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.187392e-02 | 1.925 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.185684e-02 | 1.926 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.236061e-02 | 1.908 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.201640e-02 | 1.920 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.071951e-02 | 1.970 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.048026e-02 | 1.980 | 1 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.236488e-02 | 1.908 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.161075e-02 | 1.935 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.247812e-02 | 1.904 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.236061e-02 | 1.908 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.134053e-02 | 1.945 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.079718e-02 | 1.967 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.275406e-02 | 1.894 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.331440e-02 | 1.876 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.356858e-02 | 1.867 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.425311e-02 | 1.846 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.445045e-02 | 1.840 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 1.464151e-02 | 1.834 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.485261e-02 | 1.828 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.485261e-02 | 1.828 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.488457e-02 | 1.827 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.488457e-02 | 1.827 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.502378e-02 | 1.823 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.537786e-02 | 1.813 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.547698e-02 | 1.810 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.547698e-02 | 1.810 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.588704e-02 | 1.799 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.627669e-02 | 1.788 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.635644e-02 | 1.786 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.635644e-02 | 1.786 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.655744e-02 | 1.781 | 1 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.723234e-02 | 1.764 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.723234e-02 | 1.764 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.731160e-02 | 1.762 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.731160e-02 | 1.762 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.734918e-02 | 1.761 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.763626e-02 | 1.754 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.763626e-02 | 1.754 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.763626e-02 | 1.754 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.794160e-02 | 1.746 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.808481e-02 | 1.743 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 1.810713e-02 | 1.742 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.810713e-02 | 1.742 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.811351e-02 | 1.742 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.855945e-02 | 1.731 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.870550e-02 | 1.728 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.870626e-02 | 1.728 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.880462e-02 | 1.726 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.880462e-02 | 1.726 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.940405e-02 | 1.712 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.940405e-02 | 1.712 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.950385e-02 | 1.710 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.986275e-02 | 1.702 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.016363e-02 | 1.695 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 2.070860e-02 | 1.684 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.076270e-02 | 1.683 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.076270e-02 | 1.683 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.084705e-02 | 1.681 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.377564e-02 | 1.624 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.377564e-02 | 1.624 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.238861e-02 | 1.650 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.238861e-02 | 1.650 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.293502e-02 | 1.640 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.484605e-02 | 1.605 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.484605e-02 | 1.605 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.592939e-02 | 1.586 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.592939e-02 | 1.586 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.592939e-02 | 1.586 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 2.570114e-02 | 1.590 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.505192e-02 | 1.601 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.187252e-02 | 1.660 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.572848e-02 | 1.590 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.264996e-02 | 1.645 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.238861e-02 | 1.650 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 2.127330e-02 | 1.672 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 2.238861e-02 | 1.650 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.592939e-02 | 1.586 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.612747e-02 | 1.583 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.293502e-02 | 1.640 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.600485e-02 | 1.585 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.619194e-02 | 1.582 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.636432e-02 | 1.579 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.642372e-02 | 1.578 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.645844e-02 | 1.577 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 2.645844e-02 | 1.577 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.693789e-02 | 1.570 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.693789e-02 | 1.570 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.706447e-02 | 1.568 | 1 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 2.756888e-02 | 1.560 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.833249e-02 | 1.548 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.930971e-02 | 1.533 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.930971e-02 | 1.533 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.939778e-02 | 1.532 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.975827e-02 | 1.526 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.984076e-02 | 1.525 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.988150e-02 | 1.525 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.027596e-02 | 1.519 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.027596e-02 | 1.519 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.098801e-02 | 1.509 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.124989e-02 | 1.505 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.128187e-02 | 1.505 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 3.173608e-02 | 1.498 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.198377e-02 | 1.495 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.198377e-02 | 1.495 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.235686e-02 | 1.490 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 3.268088e-02 | 1.486 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.268088e-02 | 1.486 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.268088e-02 | 1.486 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.429463e-02 | 1.465 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 3.439126e-02 | 1.464 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.499883e-02 | 1.456 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.550585e-02 | 1.450 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.550585e-02 | 1.450 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 3.553112e-02 | 1.449 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.553112e-02 | 1.449 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 3.602131e-02 | 1.443 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 3.602131e-02 | 1.443 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.665670e-02 | 1.436 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.665670e-02 | 1.436 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.841475e-02 | 1.416 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.841475e-02 | 1.416 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.969341e-02 | 1.304 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.969341e-02 | 1.304 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.969341e-02 | 1.304 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 4.220803e-02 | 1.375 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 4.570465e-02 | 1.340 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.748038e-02 | 1.323 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.748038e-02 | 1.323 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.748038e-02 | 1.323 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.896764e-02 | 1.409 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 3.854226e-02 | 1.414 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 3.854226e-02 | 1.414 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.854226e-02 | 1.414 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 4.287754e-02 | 1.368 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.116079e-02 | 1.386 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 4.753320e-02 | 1.323 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 3.759273e-02 | 1.425 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.633156e-02 | 1.334 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.633156e-02 | 1.334 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.379620e-02 | 1.359 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.996759e-02 | 1.398 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 4.247570e-02 | 1.372 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 4.461014e-02 | 1.351 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.699116e-02 | 1.328 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 4.748038e-02 | 1.323 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 4.116079e-02 | 1.386 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 3.881457e-02 | 1.411 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 4.748038e-02 | 1.323 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.287754e-02 | 1.368 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 4.078645e-02 | 1.389 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.587078e-02 | 1.338 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 4.570465e-02 | 1.340 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.190188e-02 | 1.378 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 3.780187e-02 | 1.422 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.753320e-02 | 1.323 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.651389e-02 | 1.332 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 3.757333e-02 | 1.425 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.822752e-02 | 1.317 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 4.171876e-02 | 1.380 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 4.447624e-02 | 1.352 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 3.759273e-02 | 1.425 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.886132e-02 | 1.410 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.980214e-02 | 1.303 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.980214e-02 | 1.303 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.115002e-02 | 1.291 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.126616e-02 | 1.290 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.141398e-02 | 1.289 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.172675e-02 | 1.286 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 5.179190e-02 | 1.286 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 5.201557e-02 | 1.284 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 5.201557e-02 | 1.284 | 1 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.209290e-02 | 1.283 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.217454e-02 | 1.283 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 5.231167e-02 | 1.281 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 5.234268e-02 | 1.281 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.234268e-02 | 1.281 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 5.235401e-02 | 1.281 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 5.284212e-02 | 1.277 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 5.333468e-02 | 1.273 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 5.456221e-02 | 1.263 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 5.526855e-02 | 1.258 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 5.721302e-02 | 1.243 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.721302e-02 | 1.243 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.721302e-02 | 1.243 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 5.721302e-02 | 1.243 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 5.734001e-02 | 1.242 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 5.745900e-02 | 1.241 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.760922e-02 | 1.240 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.760922e-02 | 1.240 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 5.760922e-02 | 1.240 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 5.804864e-02 | 1.236 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 5.804864e-02 | 1.236 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 5.880743e-02 | 1.231 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.887928e-02 | 1.230 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 6.037689e-02 | 1.219 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.037689e-02 | 1.219 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 6.037689e-02 | 1.219 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 6.108144e-02 | 1.214 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.119846e-02 | 1.213 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 6.188430e-02 | 1.208 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 6.227086e-02 | 1.206 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.227086e-02 | 1.206 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.227086e-02 | 1.206 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 6.236321e-02 | 1.205 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 6.325306e-02 | 1.199 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.417715e-02 | 1.193 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.436697e-02 | 1.191 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 6.463474e-02 | 1.190 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 6.484942e-02 | 1.188 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.484942e-02 | 1.188 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 6.595725e-02 | 1.181 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 6.673315e-02 | 1.176 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 6.673315e-02 | 1.176 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 6.673315e-02 | 1.176 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 6.843080e-02 | 1.165 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 6.958462e-02 | 1.157 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 6.958462e-02 | 1.157 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 6.967326e-02 | 1.157 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 7.027475e-02 | 1.153 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 7.032749e-02 | 1.153 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.032749e-02 | 1.153 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 7.044116e-02 | 1.152 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 7.051344e-02 | 1.152 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 7.051344e-02 | 1.152 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 7.067822e-02 | 1.151 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.126335e-02 | 1.147 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.126335e-02 | 1.147 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 7.126335e-02 | 1.147 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 7.162324e-02 | 1.145 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 7.336401e-02 | 1.135 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 7.359000e-02 | 1.133 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.399675e-02 | 1.131 | 1 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 7.488334e-02 | 1.126 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 7.505980e-02 | 1.125 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 7.505980e-02 | 1.125 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 7.651819e-02 | 1.116 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.651819e-02 | 1.116 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 7.651819e-02 | 1.116 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 7.713545e-02 | 1.113 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 7.713545e-02 | 1.113 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 7.713545e-02 | 1.113 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.798137e-02 | 1.108 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 7.798137e-02 | 1.108 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 7.894153e-02 | 1.103 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 7.920593e-02 | 1.101 | 1 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 7.964419e-02 | 1.099 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 7.965658e-02 | 1.099 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 7.965658e-02 | 1.099 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 8.009344e-02 | 1.096 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 8.021349e-02 | 1.096 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 8.138685e-02 | 1.089 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 8.138685e-02 | 1.089 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.138685e-02 | 1.089 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 8.340025e-02 | 1.079 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 8.407552e-02 | 1.075 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 8.407552e-02 | 1.075 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 8.444565e-02 | 1.073 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.444565e-02 | 1.073 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 1.014688e-01 | 0.994 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 1.014688e-01 | 0.994 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 1.014688e-01 | 0.994 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 9.419107e-02 | 1.026 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 9.419107e-02 | 1.026 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 9.419107e-02 | 1.026 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 9.419107e-02 | 1.026 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 1.068056e-01 | 0.971 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 8.662355e-02 | 1.062 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 8.662355e-02 | 1.062 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.662355e-02 | 1.062 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 8.662355e-02 | 1.062 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 1.092540e-01 | 0.962 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.794141e-02 | 1.056 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 8.794141e-02 | 1.056 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 8.667895e-02 | 1.062 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.075023e-01 | 0.969 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.038364e-01 | 0.984 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.038364e-01 | 0.984 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.226861e-01 | 0.911 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.159469e-01 | 0.936 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 1.159469e-01 | 0.936 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 9.650502e-02 | 1.015 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.253216e-01 | 0.902 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.024295e-01 | 0.990 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 8.746831e-02 | 1.058 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 1.266960e-01 | 0.897 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.140781e-01 | 0.943 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 9.650502e-02 | 1.015 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.002166e-01 | 0.999 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.002166e-01 | 0.999 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.266960e-01 | 0.897 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 1.075023e-01 | 0.969 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.092368e-01 | 0.962 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.266960e-01 | 0.897 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.226861e-01 | 0.911 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.254999e-01 | 0.901 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 9.650502e-02 | 1.015 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 1.136838e-01 | 0.944 | 1 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.159469e-01 | 0.936 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 1.136838e-01 | 0.944 | 1 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 9.419107e-02 | 1.026 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 1.092540e-01 | 0.962 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 1.226861e-01 | 0.911 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 1.149941e-01 | 0.939 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.002166e-01 | 0.999 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.014688e-01 | 0.994 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.580744e-02 | 1.019 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.580744e-02 | 1.019 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.102610e-01 | 0.958 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 9.438000e-02 | 1.025 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 9.438000e-02 | 1.025 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.552586e-02 | 1.068 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 1.073765e-01 | 0.969 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 1.214184e-01 | 0.916 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.060365e-02 | 1.043 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.009273e-01 | 0.996 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 1.039595e-01 | 0.983 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 1.240960e-01 | 0.906 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 1.068056e-01 | 0.971 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 1.266960e-01 | 0.897 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 9.557282e-02 | 1.020 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.179099e-01 | 0.928 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.060365e-02 | 1.043 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 1.024295e-01 | 0.990 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.255428e-01 | 0.901 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 1.275741e-01 | 0.894 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.286960e-01 | 0.890 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.286960e-01 | 0.890 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.291013e-01 | 0.889 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 1.292979e-01 | 0.888 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.314408e-01 | 0.881 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 1.319305e-01 | 0.880 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.319305e-01 | 0.880 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 1.319305e-01 | 0.880 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.319305e-01 | 0.880 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.319305e-01 | 0.880 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.326703e-01 | 0.877 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 1.328835e-01 | 0.877 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.340020e-01 | 0.873 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.340020e-01 | 0.873 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 1.342950e-01 | 0.872 | 1 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 1.344422e-01 | 0.871 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.344422e-01 | 0.871 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 1.346201e-01 | 0.871 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.346201e-01 | 0.871 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.355177e-01 | 0.868 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.363457e-01 | 0.865 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.369683e-01 | 0.863 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.369683e-01 | 0.863 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 1.369683e-01 | 0.863 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.369683e-01 | 0.863 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.369683e-01 | 0.863 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.373464e-01 | 0.862 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.374186e-01 | 0.862 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.374687e-01 | 0.862 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.374687e-01 | 0.862 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.374687e-01 | 0.862 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.378224e-01 | 0.861 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 1.384833e-01 | 0.859 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.431509e-01 | 0.844 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 1.431509e-01 | 0.844 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.464955e-01 | 0.834 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.475431e-01 | 0.831 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.520621e-01 | 0.818 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.526047e-01 | 0.816 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.533922e-01 | 0.814 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.550943e-01 | 0.809 | 1 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.551189e-01 | 0.809 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.553096e-01 | 0.809 | 1 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.563808e-01 | 0.806 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.571608e-01 | 0.804 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.571608e-01 | 0.804 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 1.577312e-01 | 0.802 | 1 | 1 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.583401e-01 | 0.800 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.583401e-01 | 0.800 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.604072e-01 | 0.795 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.611612e-01 | 0.793 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 1.611612e-01 | 0.793 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.611612e-01 | 0.793 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 1.614510e-01 | 0.792 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 1.614510e-01 | 0.792 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.619482e-01 | 0.791 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.619482e-01 | 0.791 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.619482e-01 | 0.791 | 0 | 0 |
| Drug resistance of ALK mutants | R-HSA-9700649 | 1.637722e-01 | 0.786 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.637722e-01 | 0.786 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.637722e-01 | 0.786 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.637722e-01 | 0.786 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.637722e-01 | 0.786 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.637722e-01 | 0.786 | 0 | 0 |
| ASP-3026-resistant ALK mutants | R-HSA-9717264 | 1.637722e-01 | 0.786 | 0 | 0 |
| crizotinib-resistant ALK mutants | R-HSA-9717326 | 1.637722e-01 | 0.786 | 0 | 0 |
| NVP-TAE684-resistant ALK mutants | R-HSA-9717301 | 1.637722e-01 | 0.786 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.637722e-01 | 0.786 | 0 | 0 |
| lorlatinib-resistant ALK mutants | R-HSA-9717329 | 1.637722e-01 | 0.786 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.637722e-01 | 0.786 | 0 | 0 |
| ceritinib-resistant ALK mutants | R-HSA-9717323 | 1.637722e-01 | 0.786 | 0 | 0 |
| alectinib-resistant ALK mutants | R-HSA-9717316 | 1.637722e-01 | 0.786 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.637722e-01 | 0.786 | 0 | 0 |
| brigatinib-resistant ALK mutants | R-HSA-9717319 | 1.637722e-01 | 0.786 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.637722e-01 | 0.786 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.637722e-01 | 0.786 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.637722e-01 | 0.786 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.637722e-01 | 0.786 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.637722e-01 | 0.786 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.637722e-01 | 0.786 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.637722e-01 | 0.786 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.637722e-01 | 0.786 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.637722e-01 | 0.786 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.637722e-01 | 0.786 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.637722e-01 | 0.786 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.637722e-01 | 0.786 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 1.638575e-01 | 0.786 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.651287e-01 | 0.782 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.651287e-01 | 0.782 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.667406e-01 | 0.778 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.667406e-01 | 0.778 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.680676e-01 | 0.775 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.684621e-01 | 0.773 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.687456e-01 | 0.773 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.693461e-01 | 0.771 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.701100e-01 | 0.769 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.701100e-01 | 0.769 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.710802e-01 | 0.767 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 1.739564e-01 | 0.760 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.739564e-01 | 0.760 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 1.739564e-01 | 0.760 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 1.739564e-01 | 0.760 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.740372e-01 | 0.759 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.778459e-01 | 0.750 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.786402e-01 | 0.748 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 1.786402e-01 | 0.748 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.792945e-01 | 0.746 | 1 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.792945e-01 | 0.746 | 1 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.792945e-01 | 0.746 | 1 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.799385e-01 | 0.745 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.799385e-01 | 0.745 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.804922e-01 | 0.744 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 1.806095e-01 | 0.743 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 1.823996e-01 | 0.739 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.884965e-01 | 0.725 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.886517e-01 | 0.724 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.894020e-01 | 0.723 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.924255e-01 | 0.716 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.928827e-01 | 0.715 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 1.928827e-01 | 0.715 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.940523e-01 | 0.712 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.947635e-01 | 0.710 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 1.958420e-01 | 0.708 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 1.958420e-01 | 0.708 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.962673e-01 | 0.707 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.999116e-01 | 0.699 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.045530e-01 | 0.689 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.046184e-01 | 0.689 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 2.057056e-01 | 0.687 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.057056e-01 | 0.687 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 2.057056e-01 | 0.687 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.057056e-01 | 0.687 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 2.057056e-01 | 0.687 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 2.057056e-01 | 0.687 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.057056e-01 | 0.687 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 3.007308e-01 | 0.522 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 3.007308e-01 | 0.522 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 3.007308e-01 | 0.522 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 3.007308e-01 | 0.522 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 3.007308e-01 | 0.522 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 3.007308e-01 | 0.522 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 3.007308e-01 | 0.522 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 2.254059e-01 | 0.647 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 2.254059e-01 | 0.647 | 0 | 0 |
| Signaling by FGFR2 amplification mutants | R-HSA-2023837 | 2.254059e-01 | 0.647 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 2.254059e-01 | 0.647 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 2.254059e-01 | 0.647 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 2.254059e-01 | 0.647 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 2.254059e-01 | 0.647 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 2.254059e-01 | 0.647 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 2.254059e-01 | 0.647 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 2.191069e-01 | 0.659 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.191069e-01 | 0.659 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 2.191069e-01 | 0.659 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.191069e-01 | 0.659 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.191069e-01 | 0.659 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 2.911121e-01 | 0.536 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.911121e-01 | 0.536 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 2.911121e-01 | 0.536 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.911121e-01 | 0.536 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.911121e-01 | 0.536 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 4.152647e-01 | 0.382 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 4.152647e-01 | 0.382 | 0 | 0 |
| t(4;14) translocations of FGFR3 | R-HSA-2033515 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by FGFR3 fusions in cancer | R-HSA-8853334 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by FGFR2 fusions | R-HSA-8853333 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 4.152647e-01 | 0.382 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 4.152647e-01 | 0.382 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 4.152647e-01 | 0.382 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 4.152647e-01 | 0.382 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 4.152647e-01 | 0.382 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 4.152647e-01 | 0.382 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 4.152647e-01 | 0.382 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 4.152647e-01 | 0.382 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 4.152647e-01 | 0.382 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 4.152647e-01 | 0.382 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 4.152647e-01 | 0.382 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 4.152647e-01 | 0.382 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 4.152647e-01 | 0.382 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 2.662802e-01 | 0.575 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.662802e-01 | 0.575 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.662802e-01 | 0.575 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.662802e-01 | 0.575 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 2.662802e-01 | 0.575 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.662802e-01 | 0.575 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 2.662802e-01 | 0.575 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 2.662802e-01 | 0.575 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.662802e-01 | 0.575 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 2.662802e-01 | 0.575 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.432077e-01 | 0.614 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 3.560787e-01 | 0.448 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 3.560787e-01 | 0.448 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 3.560787e-01 | 0.448 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 3.560787e-01 | 0.448 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.144800e-01 | 0.502 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 3.144800e-01 | 0.502 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 3.144800e-01 | 0.502 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.144800e-01 | 0.502 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 3.144800e-01 | 0.502 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 2.820715e-01 | 0.550 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 2.820715e-01 | 0.550 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.554039e-01 | 0.593 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.554039e-01 | 0.593 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.327524e-01 | 0.633 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.131136e-01 | 0.671 | 1 | 1 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 2.891139e-01 | 0.539 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.891139e-01 | 0.539 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.891139e-01 | 0.539 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.891139e-01 | 0.539 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 3.217743e-01 | 0.492 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.217743e-01 | 0.492 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 3.217743e-01 | 0.492 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 3.217743e-01 | 0.492 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 3.217743e-01 | 0.492 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.217743e-01 | 0.492 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 3.217743e-01 | 0.492 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.628380e-01 | 0.440 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 3.628380e-01 | 0.440 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.628380e-01 | 0.440 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.628380e-01 | 0.440 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 2.424899e-01 | 0.615 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.235498e-01 | 0.490 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.670894e-01 | 0.573 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 3.618295e-01 | 0.441 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.106230e-01 | 0.387 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.106230e-01 | 0.387 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 4.106230e-01 | 0.387 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 2.100617e-01 | 0.678 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.100617e-01 | 0.678 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 3.208699e-01 | 0.494 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 4.017960e-01 | 0.396 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.150982e-01 | 0.502 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.492826e-01 | 0.457 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.117744e-01 | 0.506 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 3.395447e-01 | 0.469 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.854026e-01 | 0.414 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 3.779451e-01 | 0.423 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.066956e-01 | 0.391 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.066956e-01 | 0.391 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.975711e-01 | 0.401 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 3.863571e-01 | 0.413 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.121970e-01 | 0.673 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 3.642798e-01 | 0.439 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.975711e-01 | 0.401 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 3.144800e-01 | 0.502 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.131136e-01 | 0.671 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 3.074076e-01 | 0.512 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 2.920906e-01 | 0.534 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.260839e-01 | 0.646 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.424899e-01 | 0.615 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 3.492826e-01 | 0.457 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.928751e-01 | 0.533 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 2.486853e-01 | 0.604 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.217743e-01 | 0.492 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 3.208699e-01 | 0.494 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.586440e-01 | 0.445 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 2.820715e-01 | 0.550 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 3.235498e-01 | 0.490 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.854026e-01 | 0.414 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.086174e-01 | 0.681 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.554039e-01 | 0.593 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 3.975711e-01 | 0.401 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.911121e-01 | 0.536 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 2.424899e-01 | 0.615 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 2.869467e-01 | 0.542 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 2.388259e-01 | 0.622 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.584145e-01 | 0.588 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 4.152647e-01 | 0.382 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 3.217743e-01 | 0.492 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.654697e-01 | 0.576 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.235498e-01 | 0.490 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 3.618295e-01 | 0.441 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.619820e-01 | 0.582 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 3.492826e-01 | 0.457 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 3.565609e-01 | 0.448 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.591393e-01 | 0.445 | 1 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 3.780402e-01 | 0.422 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.253665e-01 | 0.488 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.592842e-01 | 0.586 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.191069e-01 | 0.659 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.614056e-01 | 0.583 | 1 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 4.020361e-01 | 0.396 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 2.737380e-01 | 0.563 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.200148e-01 | 0.658 | 1 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.460236e-01 | 0.609 | 1 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 3.560787e-01 | 0.448 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 3.560787e-01 | 0.448 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 2.227504e-01 | 0.652 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.227504e-01 | 0.652 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.235498e-01 | 0.490 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.870137e-01 | 0.542 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.150982e-01 | 0.502 | 1 | 1 |
| Intraflagellar transport | R-HSA-5620924 | 3.047954e-01 | 0.516 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.486853e-01 | 0.604 | 1 | 0 |
| DNA Repair | R-HSA-73894 | 3.263504e-01 | 0.486 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.138673e-01 | 0.670 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.455839e-01 | 0.610 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.675063e-01 | 0.573 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.869467e-01 | 0.542 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 3.933450e-01 | 0.405 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 4.047414e-01 | 0.393 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.455839e-01 | 0.610 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.458238e-01 | 0.609 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.492826e-01 | 0.457 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.554039e-01 | 0.593 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 2.554039e-01 | 0.593 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 3.217743e-01 | 0.492 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 3.217743e-01 | 0.492 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 3.217743e-01 | 0.492 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.608611e-01 | 0.443 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.144800e-01 | 0.502 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 2.388259e-01 | 0.622 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.891139e-01 | 0.539 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 3.995926e-01 | 0.398 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.670894e-01 | 0.573 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.083187e-01 | 0.511 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.741637e-01 | 0.427 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 3.560787e-01 | 0.448 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 2.554039e-01 | 0.593 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 2.267583e-01 | 0.644 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.975711e-01 | 0.401 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 3.207351e-01 | 0.494 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 3.326965e-01 | 0.478 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 3.060533e-01 | 0.514 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 3.007308e-01 | 0.522 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 3.007308e-01 | 0.522 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 2.254059e-01 | 0.647 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 2.911121e-01 | 0.536 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 4.152647e-01 | 0.382 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 4.152647e-01 | 0.382 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 4.152647e-01 | 0.382 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 4.152647e-01 | 0.382 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 4.152647e-01 | 0.382 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 4.152647e-01 | 0.382 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.820715e-01 | 0.550 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 2.891139e-01 | 0.539 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.618295e-01 | 0.441 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.618295e-01 | 0.441 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.267583e-01 | 0.644 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.628380e-01 | 0.440 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.662802e-01 | 0.575 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 3.181870e-01 | 0.497 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.811112e-01 | 0.419 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 4.152647e-01 | 0.382 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 4.152647e-01 | 0.382 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 3.628380e-01 | 0.440 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.136987e-01 | 0.670 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.432077e-01 | 0.614 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 3.560787e-01 | 0.448 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.216657e-01 | 0.654 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.060685e-01 | 0.514 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 4.159383e-01 | 0.381 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 4.167756e-01 | 0.380 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 4.178068e-01 | 0.379 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 4.187860e-01 | 0.378 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 4.187860e-01 | 0.378 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 4.187860e-01 | 0.378 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 4.187860e-01 | 0.378 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 4.187860e-01 | 0.378 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 4.187860e-01 | 0.378 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 4.187860e-01 | 0.378 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 4.187860e-01 | 0.378 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 4.187860e-01 | 0.378 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 4.187860e-01 | 0.378 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 4.187860e-01 | 0.378 | 0 | 0 |
| Proton/oligopeptide cotransporters | R-HSA-427975 | 4.187860e-01 | 0.378 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 4.189058e-01 | 0.378 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 4.202593e-01 | 0.376 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 4.202593e-01 | 0.376 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.226081e-01 | 0.374 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 4.281285e-01 | 0.368 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 4.281285e-01 | 0.368 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.286363e-01 | 0.368 | 1 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.286363e-01 | 0.368 | 1 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 4.350713e-01 | 0.361 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.353803e-01 | 0.361 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 4.353803e-01 | 0.361 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 4.353803e-01 | 0.361 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.353803e-01 | 0.361 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 4.412843e-01 | 0.355 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 4.412843e-01 | 0.355 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 4.412843e-01 | 0.355 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.412843e-01 | 0.355 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.479502e-01 | 0.349 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.521344e-01 | 0.345 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 4.550485e-01 | 0.342 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 4.572383e-01 | 0.340 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 4.596124e-01 | 0.338 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.605178e-01 | 0.337 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 4.624942e-01 | 0.335 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.624942e-01 | 0.335 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 4.638549e-01 | 0.334 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.638549e-01 | 0.334 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 4.638549e-01 | 0.334 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.640019e-01 | 0.333 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.723365e-01 | 0.326 | 1 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.723365e-01 | 0.326 | 1 | 0 |
| HCMV Late Events | R-HSA-9610379 | 4.738659e-01 | 0.324 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.739613e-01 | 0.324 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.771642e-01 | 0.321 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 4.782317e-01 | 0.320 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 4.782317e-01 | 0.320 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 4.782317e-01 | 0.320 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 4.782317e-01 | 0.320 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 4.782317e-01 | 0.320 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 4.782317e-01 | 0.320 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 4.782317e-01 | 0.320 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 4.782317e-01 | 0.320 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 4.787496e-01 | 0.320 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.787496e-01 | 0.320 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.799586e-01 | 0.319 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 4.799586e-01 | 0.319 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 4.799586e-01 | 0.319 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 4.799586e-01 | 0.319 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.799586e-01 | 0.319 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 4.799586e-01 | 0.319 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 4.799586e-01 | 0.319 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.833489e-01 | 0.316 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.886356e-01 | 0.311 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.919865e-01 | 0.308 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.962211e-01 | 0.304 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 4.962211e-01 | 0.304 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 4.962211e-01 | 0.304 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.987409e-01 | 0.302 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.987409e-01 | 0.302 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.987409e-01 | 0.302 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 5.022138e-01 | 0.299 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.022138e-01 | 0.299 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 5.022138e-01 | 0.299 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 5.022138e-01 | 0.299 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.032018e-01 | 0.298 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 5.110444e-01 | 0.292 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 5.110444e-01 | 0.292 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 5.110444e-01 | 0.292 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 5.110444e-01 | 0.292 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 5.110444e-01 | 0.292 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 5.110444e-01 | 0.292 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 5.110444e-01 | 0.292 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 5.110444e-01 | 0.292 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 5.110444e-01 | 0.292 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 5.110444e-01 | 0.292 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 5.110444e-01 | 0.292 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 5.110444e-01 | 0.292 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 5.110444e-01 | 0.292 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 5.110444e-01 | 0.292 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 5.110444e-01 | 0.292 | 0 | 0 |
| The AIM2 inflammasome | R-HSA-844615 | 5.110444e-01 | 0.292 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 5.110444e-01 | 0.292 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 5.110444e-01 | 0.292 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 5.110444e-01 | 0.292 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 5.110444e-01 | 0.292 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 5.175371e-01 | 0.286 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.175371e-01 | 0.286 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.175371e-01 | 0.286 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 5.175371e-01 | 0.286 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 5.179659e-01 | 0.286 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 5.185581e-01 | 0.285 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 5.244705e-01 | 0.280 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 5.253058e-01 | 0.280 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.288256e-01 | 0.277 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 5.291176e-01 | 0.276 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 5.291176e-01 | 0.276 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 5.305099e-01 | 0.275 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 5.338019e-01 | 0.273 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 5.338019e-01 | 0.273 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 5.338019e-01 | 0.273 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 5.338019e-01 | 0.273 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 5.338019e-01 | 0.273 | 0 | 0 |
| SLC-mediated transport of oligopeptides | R-HSA-9959399 | 5.338019e-01 | 0.273 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 5.338019e-01 | 0.273 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 5.338019e-01 | 0.273 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.370037e-01 | 0.270 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 5.386055e-01 | 0.269 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 5.386055e-01 | 0.269 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 5.386055e-01 | 0.269 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.451947e-01 | 0.263 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 5.451947e-01 | 0.263 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 5.451947e-01 | 0.263 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.451947e-01 | 0.263 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 5.451947e-01 | 0.263 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 5.451947e-01 | 0.263 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.451947e-01 | 0.263 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.467487e-01 | 0.262 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 5.537904e-01 | 0.257 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 5.537904e-01 | 0.257 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 5.537904e-01 | 0.257 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 5.551978e-01 | 0.256 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.570441e-01 | 0.254 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.586998e-01 | 0.253 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 5.610214e-01 | 0.251 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.624493e-01 | 0.250 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.663996e-01 | 0.247 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.673994e-01 | 0.246 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 5.673994e-01 | 0.246 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 5.673994e-01 | 0.246 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 5.673994e-01 | 0.246 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 5.702393e-01 | 0.244 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 5.731751e-01 | 0.242 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.784940e-01 | 0.238 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.819170e-01 | 0.235 | 0 | 0 |
| RSK activation | R-HSA-444257 | 5.851715e-01 | 0.233 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 5.851715e-01 | 0.233 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 5.851715e-01 | 0.233 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 5.851715e-01 | 0.233 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 5.851715e-01 | 0.233 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 5.859275e-01 | 0.232 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 5.859275e-01 | 0.232 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.859275e-01 | 0.232 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 5.859275e-01 | 0.232 | 1 | 1 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.859275e-01 | 0.232 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 5.859275e-01 | 0.232 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 5.885384e-01 | 0.230 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.885384e-01 | 0.230 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 5.885384e-01 | 0.230 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 5.905980e-01 | 0.229 | 0 | 0 |
| The NLRP1 inflammasome | R-HSA-844455 | 5.911399e-01 | 0.228 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.911399e-01 | 0.228 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 5.911399e-01 | 0.228 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 5.911399e-01 | 0.228 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 5.911399e-01 | 0.228 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 5.911399e-01 | 0.228 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 5.911399e-01 | 0.228 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 5.911399e-01 | 0.228 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 5.911399e-01 | 0.228 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 5.911399e-01 | 0.228 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 5.911399e-01 | 0.228 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.911399e-01 | 0.228 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.911399e-01 | 0.228 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 5.911399e-01 | 0.228 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 5.911399e-01 | 0.228 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.911399e-01 | 0.228 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 5.911399e-01 | 0.228 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 5.911399e-01 | 0.228 | 0 | 0 |
| Activation of BMF and translocation to mitochondria | R-HSA-139910 | 5.911399e-01 | 0.228 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 5.911399e-01 | 0.228 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 5.911399e-01 | 0.228 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 5.911399e-01 | 0.228 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 5.917987e-01 | 0.228 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.925139e-01 | 0.227 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.952930e-01 | 0.225 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 5.952930e-01 | 0.225 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 5.952930e-01 | 0.225 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 5.988504e-01 | 0.223 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 5.988504e-01 | 0.223 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 6.023933e-01 | 0.220 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 6.023933e-01 | 0.220 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 6.023933e-01 | 0.220 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 6.023933e-01 | 0.220 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.031103e-01 | 0.220 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 6.082373e-01 | 0.216 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 6.122636e-01 | 0.213 | 0 | 0 |
| Immune System | R-HSA-168256 | 6.146948e-01 | 0.211 | 1 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 6.213430e-01 | 0.207 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 6.213430e-01 | 0.207 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 6.213430e-01 | 0.207 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 6.216459e-01 | 0.206 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.216459e-01 | 0.206 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.216459e-01 | 0.206 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.216459e-01 | 0.206 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 6.237047e-01 | 0.205 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 6.242459e-01 | 0.205 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 6.242459e-01 | 0.205 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 6.242459e-01 | 0.205 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 6.242459e-01 | 0.205 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 6.242459e-01 | 0.205 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 6.277017e-01 | 0.202 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 6.322254e-01 | 0.199 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 6.322254e-01 | 0.199 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 6.322254e-01 | 0.199 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 6.322254e-01 | 0.199 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 6.322254e-01 | 0.199 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 6.322254e-01 | 0.199 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 6.322254e-01 | 0.199 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 6.322254e-01 | 0.199 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 6.322254e-01 | 0.199 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.339690e-01 | 0.198 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.367584e-01 | 0.196 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 6.476800e-01 | 0.189 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 6.480292e-01 | 0.188 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 6.480292e-01 | 0.188 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 6.480292e-01 | 0.188 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.490698e-01 | 0.188 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.495733e-01 | 0.187 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 6.495733e-01 | 0.187 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 6.495733e-01 | 0.187 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 6.495733e-01 | 0.187 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.514059e-01 | 0.186 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.522652e-01 | 0.186 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 6.530192e-01 | 0.185 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 6.581188e-01 | 0.182 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 6.581188e-01 | 0.182 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 6.581188e-01 | 0.182 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 6.581188e-01 | 0.182 | 0 | 0 |
| MDK and PTN in ALK signaling | R-HSA-9851151 | 6.581188e-01 | 0.182 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 6.581188e-01 | 0.182 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 6.581188e-01 | 0.182 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 6.581188e-01 | 0.182 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 6.581188e-01 | 0.182 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 6.581188e-01 | 0.182 | 0 | 0 |
| Interleukin-38 signaling | R-HSA-9007892 | 6.581188e-01 | 0.182 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.600575e-01 | 0.180 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 6.600575e-01 | 0.180 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.600575e-01 | 0.180 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.600575e-01 | 0.180 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 6.600575e-01 | 0.180 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.600575e-01 | 0.180 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 6.619438e-01 | 0.179 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.696763e-01 | 0.174 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 6.749991e-01 | 0.171 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 6.749991e-01 | 0.171 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 6.749991e-01 | 0.171 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 6.749991e-01 | 0.171 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 6.749991e-01 | 0.171 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 6.749991e-01 | 0.171 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 6.749991e-01 | 0.171 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 6.749991e-01 | 0.171 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 6.764319e-01 | 0.170 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.764319e-01 | 0.170 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 6.782928e-01 | 0.169 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.826002e-01 | 0.166 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 6.826002e-01 | 0.166 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 6.826002e-01 | 0.166 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 6.826002e-01 | 0.166 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 6.904978e-01 | 0.161 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.928218e-01 | 0.159 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.928218e-01 | 0.159 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 6.928218e-01 | 0.159 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 6.933305e-01 | 0.159 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 6.933305e-01 | 0.159 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 6.959357e-01 | 0.157 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 7.018822e-01 | 0.154 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 7.063866e-01 | 0.151 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.103625e-01 | 0.149 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.103625e-01 | 0.149 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 7.104700e-01 | 0.148 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.106439e-01 | 0.148 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 7.136320e-01 | 0.147 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 7.136320e-01 | 0.147 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 7.136320e-01 | 0.147 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.136320e-01 | 0.147 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.136320e-01 | 0.147 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.136320e-01 | 0.147 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.136320e-01 | 0.147 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 7.141285e-01 | 0.146 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 7.141285e-01 | 0.146 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 7.141285e-01 | 0.146 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 7.141285e-01 | 0.146 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.141285e-01 | 0.146 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 7.141285e-01 | 0.146 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 7.141285e-01 | 0.146 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 7.141285e-01 | 0.146 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 7.141285e-01 | 0.146 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 7.141285e-01 | 0.146 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 7.141285e-01 | 0.146 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 7.141285e-01 | 0.146 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 7.141285e-01 | 0.146 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 7.141285e-01 | 0.146 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 7.141285e-01 | 0.146 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 7.192065e-01 | 0.143 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 7.199275e-01 | 0.143 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 7.240819e-01 | 0.140 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 7.240819e-01 | 0.140 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.240819e-01 | 0.140 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 7.259067e-01 | 0.139 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 7.259067e-01 | 0.139 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 7.295768e-01 | 0.137 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.363065e-01 | 0.133 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.363065e-01 | 0.133 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.363065e-01 | 0.133 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 7.401078e-01 | 0.131 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 7.401078e-01 | 0.131 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.405939e-01 | 0.130 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.405939e-01 | 0.130 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.426991e-01 | 0.129 | 1 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.460187e-01 | 0.127 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.460187e-01 | 0.127 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.460187e-01 | 0.127 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.478091e-01 | 0.126 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 7.480240e-01 | 0.126 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 7.483326e-01 | 0.126 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.483326e-01 | 0.126 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 7.483326e-01 | 0.126 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 7.483326e-01 | 0.126 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.483326e-01 | 0.126 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 7.483326e-01 | 0.126 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 7.483326e-01 | 0.126 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 7.483326e-01 | 0.126 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.485042e-01 | 0.126 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 7.485042e-01 | 0.126 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.485042e-01 | 0.126 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.523673e-01 | 0.124 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 7.523673e-01 | 0.124 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 7.523673e-01 | 0.124 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 7.523673e-01 | 0.124 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 7.523673e-01 | 0.124 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 7.523673e-01 | 0.124 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.531418e-01 | 0.123 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 7.565334e-01 | 0.121 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 7.604549e-01 | 0.119 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.604549e-01 | 0.119 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.604549e-01 | 0.119 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.604549e-01 | 0.119 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 7.604549e-01 | 0.119 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 7.609649e-01 | 0.119 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 7.609649e-01 | 0.119 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 7.609649e-01 | 0.119 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 7.609649e-01 | 0.119 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 7.609649e-01 | 0.119 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 7.609649e-01 | 0.119 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 7.609649e-01 | 0.119 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 7.609649e-01 | 0.119 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 7.609649e-01 | 0.119 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 7.609649e-01 | 0.119 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 7.609649e-01 | 0.119 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 7.609649e-01 | 0.119 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 7.609649e-01 | 0.119 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 7.609649e-01 | 0.119 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 7.609649e-01 | 0.119 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 7.609649e-01 | 0.119 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 7.609649e-01 | 0.119 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 7.634388e-01 | 0.117 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 7.653702e-01 | 0.116 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 7.653702e-01 | 0.116 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.668377e-01 | 0.115 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.696878e-01 | 0.114 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.696878e-01 | 0.114 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.712428e-01 | 0.113 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 7.720108e-01 | 0.112 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 7.720108e-01 | 0.112 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 7.720108e-01 | 0.112 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 7.720108e-01 | 0.112 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 7.720108e-01 | 0.112 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 7.782716e-01 | 0.109 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 7.782716e-01 | 0.109 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 7.782716e-01 | 0.109 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 7.782716e-01 | 0.109 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.782716e-01 | 0.109 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 7.782716e-01 | 0.109 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 7.793524e-01 | 0.108 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 7.793524e-01 | 0.108 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 7.793524e-01 | 0.108 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 7.793524e-01 | 0.108 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 7.816455e-01 | 0.107 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 7.828487e-01 | 0.106 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 7.914284e-01 | 0.102 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 7.914284e-01 | 0.102 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 7.963457e-01 | 0.099 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 8.001300e-01 | 0.097 | 0 | 0 |
| Metabolism of ingested MeSeO2H into MeSeH | R-HSA-5263617 | 8.001300e-01 | 0.097 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 8.001300e-01 | 0.097 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 8.001300e-01 | 0.097 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 8.001300e-01 | 0.097 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 8.001300e-01 | 0.097 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 8.001300e-01 | 0.097 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 8.001300e-01 | 0.097 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.006330e-01 | 0.097 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 8.019013e-01 | 0.096 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 8.019013e-01 | 0.096 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 8.019013e-01 | 0.096 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 8.019013e-01 | 0.096 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.019013e-01 | 0.096 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 8.019013e-01 | 0.096 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 8.019013e-01 | 0.096 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.035438e-01 | 0.095 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 8.044772e-01 | 0.094 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 8.069658e-01 | 0.093 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 8.069658e-01 | 0.093 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.069658e-01 | 0.093 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 8.069658e-01 | 0.093 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.069658e-01 | 0.093 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.079248e-01 | 0.093 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 8.079248e-01 | 0.093 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.226070e-01 | 0.085 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.226070e-01 | 0.085 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 8.226070e-01 | 0.085 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 8.233778e-01 | 0.084 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 8.233778e-01 | 0.084 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 8.233778e-01 | 0.084 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 8.233778e-01 | 0.084 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 8.233778e-01 | 0.084 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 8.233778e-01 | 0.084 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.233778e-01 | 0.084 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 8.250570e-01 | 0.084 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 8.250570e-01 | 0.084 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.250570e-01 | 0.084 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.314562e-01 | 0.080 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.314562e-01 | 0.080 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.314562e-01 | 0.080 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.314562e-01 | 0.080 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.314562e-01 | 0.080 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.314562e-01 | 0.080 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.314562e-01 | 0.080 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 8.328798e-01 | 0.079 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 8.328798e-01 | 0.079 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 8.328798e-01 | 0.079 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 8.328798e-01 | 0.079 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 8.328798e-01 | 0.079 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 8.328798e-01 | 0.079 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 8.328798e-01 | 0.079 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 8.328798e-01 | 0.079 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 8.328798e-01 | 0.079 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 8.328798e-01 | 0.079 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 8.328798e-01 | 0.079 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 8.328798e-01 | 0.079 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 8.328798e-01 | 0.079 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 8.328798e-01 | 0.079 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 8.328798e-01 | 0.079 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.401138e-01 | 0.076 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 8.401138e-01 | 0.076 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.401138e-01 | 0.076 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.401138e-01 | 0.076 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 8.409293e-01 | 0.075 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 8.409293e-01 | 0.075 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 8.428321e-01 | 0.074 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.428321e-01 | 0.074 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 8.428321e-01 | 0.074 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.443928e-01 | 0.073 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.443928e-01 | 0.073 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 8.446306e-01 | 0.073 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.531055e-01 | 0.069 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.531055e-01 | 0.069 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 8.531055e-01 | 0.069 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.531055e-01 | 0.069 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 8.531055e-01 | 0.069 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 8.531055e-01 | 0.069 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.531055e-01 | 0.069 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.531055e-01 | 0.069 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 8.531055e-01 | 0.069 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 8.555966e-01 | 0.068 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.558309e-01 | 0.068 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.561455e-01 | 0.067 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 8.602650e-01 | 0.065 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 8.602650e-01 | 0.065 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 8.602650e-01 | 0.065 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 8.602650e-01 | 0.065 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 8.602650e-01 | 0.065 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 8.602650e-01 | 0.065 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 8.602650e-01 | 0.065 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 8.602650e-01 | 0.065 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 8.602650e-01 | 0.065 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 8.602650e-01 | 0.065 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 8.602650e-01 | 0.065 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 8.602650e-01 | 0.065 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.604002e-01 | 0.065 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.661510e-01 | 0.062 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 8.707869e-01 | 0.060 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.721870e-01 | 0.059 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.721870e-01 | 0.059 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.721870e-01 | 0.059 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 8.721870e-01 | 0.059 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.721870e-01 | 0.059 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 8.727042e-01 | 0.059 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.762196e-01 | 0.057 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 8.831640e-01 | 0.054 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 8.831640e-01 | 0.054 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 8.831640e-01 | 0.054 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 8.831640e-01 | 0.054 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 8.831640e-01 | 0.054 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 8.831640e-01 | 0.054 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 8.831640e-01 | 0.054 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 8.831640e-01 | 0.054 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 8.831640e-01 | 0.054 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.841249e-01 | 0.053 | 0 | 0 |
| Disease | R-HSA-1643685 | 8.886418e-01 | 0.051 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 8.889609e-01 | 0.051 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 8.889609e-01 | 0.051 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.889609e-01 | 0.051 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 8.889609e-01 | 0.051 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.889609e-01 | 0.051 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 8.889609e-01 | 0.051 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 8.889609e-01 | 0.051 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.901004e-01 | 0.051 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 8.904265e-01 | 0.050 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 8.904265e-01 | 0.050 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.908168e-01 | 0.050 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.918541e-01 | 0.050 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.962463e-01 | 0.048 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.962463e-01 | 0.048 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.962463e-01 | 0.048 | 0 | 0 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | R-HSA-629594 | 9.023115e-01 | 0.045 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 9.023115e-01 | 0.045 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 9.023115e-01 | 0.045 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 9.023115e-01 | 0.045 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 9.023115e-01 | 0.045 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 9.031538e-01 | 0.044 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 9.031538e-01 | 0.044 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.031538e-01 | 0.044 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.034098e-01 | 0.044 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 9.036709e-01 | 0.044 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 9.036709e-01 | 0.044 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.036709e-01 | 0.044 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.036709e-01 | 0.044 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.068283e-01 | 0.042 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.073302e-01 | 0.042 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.100394e-01 | 0.041 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.100394e-01 | 0.041 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.108114e-01 | 0.041 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.129573e-01 | 0.040 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.145291e-01 | 0.039 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.145291e-01 | 0.039 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.145291e-01 | 0.039 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 9.145291e-01 | 0.039 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.145291e-01 | 0.039 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.145291e-01 | 0.039 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.165428e-01 | 0.038 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.165428e-01 | 0.038 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.165428e-01 | 0.038 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 9.165428e-01 | 0.038 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.165428e-01 | 0.038 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 9.165428e-01 | 0.038 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.165428e-01 | 0.038 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.177702e-01 | 0.037 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 9.183220e-01 | 0.037 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 9.183220e-01 | 0.037 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 9.183220e-01 | 0.037 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 9.183220e-01 | 0.037 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 9.183220e-01 | 0.037 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 9.183220e-01 | 0.037 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 9.183220e-01 | 0.037 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 9.183220e-01 | 0.037 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 9.183220e-01 | 0.037 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 9.183220e-01 | 0.037 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 9.183220e-01 | 0.037 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 9.183220e-01 | 0.037 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 9.183220e-01 | 0.037 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 9.183220e-01 | 0.037 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.191595e-01 | 0.037 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.208847e-01 | 0.036 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.216650e-01 | 0.035 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.216650e-01 | 0.035 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 9.216650e-01 | 0.035 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 9.216650e-01 | 0.035 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.246742e-01 | 0.034 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 9.246742e-01 | 0.034 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.254653e-01 | 0.034 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.261612e-01 | 0.033 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 9.261612e-01 | 0.033 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.268161e-01 | 0.033 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.294708e-01 | 0.032 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.304769e-01 | 0.031 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 9.317092e-01 | 0.031 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 9.317092e-01 | 0.031 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 9.317092e-01 | 0.031 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 9.317092e-01 | 0.031 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 9.317092e-01 | 0.031 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.320611e-01 | 0.031 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.337038e-01 | 0.030 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.341415e-01 | 0.030 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.342535e-01 | 0.030 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.342535e-01 | 0.030 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.342535e-01 | 0.030 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 9.342535e-01 | 0.030 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.342535e-01 | 0.030 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.367955e-01 | 0.028 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.367955e-01 | 0.028 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.367955e-01 | 0.028 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.375832e-01 | 0.028 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.375832e-01 | 0.028 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.375832e-01 | 0.028 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.415330e-01 | 0.026 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.417251e-01 | 0.026 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.417251e-01 | 0.026 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.427247e-01 | 0.026 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 9.429029e-01 | 0.026 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 9.429029e-01 | 0.026 | 0 | 0 |
| Beta oxidation of myristoyl-CoA to lauroyl-CoA | R-HSA-77285 | 9.429029e-01 | 0.026 | 0 | 0 |
| Beta oxidation of palmitoyl-CoA to myristoyl-CoA | R-HSA-77305 | 9.429029e-01 | 0.026 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.429029e-01 | 0.026 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 9.429029e-01 | 0.026 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 9.429029e-01 | 0.026 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 9.429029e-01 | 0.026 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 9.429029e-01 | 0.026 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 9.429029e-01 | 0.026 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 9.429029e-01 | 0.026 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.433301e-01 | 0.025 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.461108e-01 | 0.024 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.461108e-01 | 0.024 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.461108e-01 | 0.024 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 9.461108e-01 | 0.024 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.461108e-01 | 0.024 | 0 | 0 |
| Translation | R-HSA-72766 | 9.463459e-01 | 0.024 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.468259e-01 | 0.024 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.471355e-01 | 0.024 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 9.480697e-01 | 0.023 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 9.480697e-01 | 0.023 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.480697e-01 | 0.023 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 9.516970e-01 | 0.022 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 9.522623e-01 | 0.021 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.522623e-01 | 0.021 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 9.522623e-01 | 0.021 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.522623e-01 | 0.021 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 9.522623e-01 | 0.021 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.522623e-01 | 0.021 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 9.522623e-01 | 0.021 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 9.522623e-01 | 0.021 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 9.522623e-01 | 0.021 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.529787e-01 | 0.021 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.535206e-01 | 0.021 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 9.535206e-01 | 0.021 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.535206e-01 | 0.021 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.539297e-01 | 0.020 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.539297e-01 | 0.020 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.540589e-01 | 0.020 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.546000e-01 | 0.020 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.551348e-01 | 0.020 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.591746e-01 | 0.018 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.599497e-01 | 0.018 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.599497e-01 | 0.018 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.599497e-01 | 0.018 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 9.599497e-01 | 0.018 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.599497e-01 | 0.018 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.599497e-01 | 0.018 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 9.600879e-01 | 0.018 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 9.600879e-01 | 0.018 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.600879e-01 | 0.018 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 9.600879e-01 | 0.018 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 9.600879e-01 | 0.018 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 9.600879e-01 | 0.018 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 9.600879e-01 | 0.018 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.600879e-01 | 0.018 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 9.600879e-01 | 0.018 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.607001e-01 | 0.017 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.638619e-01 | 0.016 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.646512e-01 | 0.016 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.655204e-01 | 0.015 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.655204e-01 | 0.015 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.656114e-01 | 0.015 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.660906e-01 | 0.015 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.666311e-01 | 0.015 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.666311e-01 | 0.015 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.666311e-01 | 0.015 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 9.666311e-01 | 0.015 | 0 | 0 |
| Synthesis of 12-eicosatetraenoic acid derivatives | R-HSA-2142712 | 9.666311e-01 | 0.015 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.666311e-01 | 0.015 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.666311e-01 | 0.015 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.676848e-01 | 0.014 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.694137e-01 | 0.013 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 9.694137e-01 | 0.013 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.712355e-01 | 0.013 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.717720e-01 | 0.012 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.721019e-01 | 0.012 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.721019e-01 | 0.012 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.721019e-01 | 0.012 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 9.721019e-01 | 0.012 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.721019e-01 | 0.012 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.721019e-01 | 0.012 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 9.721019e-01 | 0.012 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.724366e-01 | 0.012 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.729979e-01 | 0.012 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.734604e-01 | 0.012 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.737483e-01 | 0.012 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 9.737483e-01 | 0.012 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.737483e-01 | 0.012 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.744013e-01 | 0.011 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.745088e-01 | 0.011 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.745088e-01 | 0.011 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.750890e-01 | 0.011 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 9.766760e-01 | 0.010 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.766760e-01 | 0.010 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.766760e-01 | 0.010 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.766760e-01 | 0.010 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 9.766760e-01 | 0.010 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | R-HSA-77288 | 9.766760e-01 | 0.010 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 9.766760e-01 | 0.010 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.766760e-01 | 0.010 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.766760e-01 | 0.010 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 9.766760e-01 | 0.010 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.766760e-01 | 0.010 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.766760e-01 | 0.010 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.766760e-01 | 0.010 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.770076e-01 | 0.010 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.770959e-01 | 0.010 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.774232e-01 | 0.010 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.780372e-01 | 0.010 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.780372e-01 | 0.010 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.780372e-01 | 0.010 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.781073e-01 | 0.010 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.781073e-01 | 0.010 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.781073e-01 | 0.010 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.792966e-01 | 0.009 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.796262e-01 | 0.009 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.799353e-01 | 0.009 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.800344e-01 | 0.009 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.805004e-01 | 0.009 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.805004e-01 | 0.009 | 0 | 0 |
| Synthesis of 15-eicosatetraenoic acid derivatives | R-HSA-2142770 | 9.805004e-01 | 0.009 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.805004e-01 | 0.009 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.805004e-01 | 0.009 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.805004e-01 | 0.009 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 9.805004e-01 | 0.009 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.817997e-01 | 0.008 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.826109e-01 | 0.008 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.836979e-01 | 0.007 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.836979e-01 | 0.007 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.837553e-01 | 0.007 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.840902e-01 | 0.007 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.848674e-01 | 0.007 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.848674e-01 | 0.007 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.850294e-01 | 0.007 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.850294e-01 | 0.007 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.855047e-01 | 0.006 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.855181e-01 | 0.006 | 1 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.855650e-01 | 0.006 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.856213e-01 | 0.006 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.861891e-01 | 0.006 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.861891e-01 | 0.006 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 9.863712e-01 | 0.006 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.863712e-01 | 0.006 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.863712e-01 | 0.006 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.863712e-01 | 0.006 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.863712e-01 | 0.006 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.863712e-01 | 0.006 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.863712e-01 | 0.006 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.863712e-01 | 0.006 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.863712e-01 | 0.006 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.867352e-01 | 0.006 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.867443e-01 | 0.006 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.868473e-01 | 0.006 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.881703e-01 | 0.005 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.886063e-01 | 0.005 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.886063e-01 | 0.005 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.886063e-01 | 0.005 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.886063e-01 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.886063e-01 | 0.005 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.889630e-01 | 0.005 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.898733e-01 | 0.004 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 9.898733e-01 | 0.004 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 9.901553e-01 | 0.004 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.904749e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.904749e-01 | 0.004 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.904749e-01 | 0.004 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.913848e-01 | 0.004 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.913873e-01 | 0.004 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.920371e-01 | 0.003 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.920371e-01 | 0.003 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.920371e-01 | 0.003 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.920371e-01 | 0.003 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.920371e-01 | 0.003 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.923970e-01 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.925325e-01 | 0.003 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.925325e-01 | 0.003 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.925914e-01 | 0.003 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.933432e-01 | 0.003 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.933432e-01 | 0.003 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.933432e-01 | 0.003 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.933432e-01 | 0.003 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.933432e-01 | 0.003 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.933928e-01 | 0.003 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.933928e-01 | 0.003 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.936681e-01 | 0.003 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.936681e-01 | 0.003 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.940914e-01 | 0.003 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.941112e-01 | 0.003 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.944352e-01 | 0.002 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.944352e-01 | 0.002 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.944352e-01 | 0.002 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.944352e-01 | 0.002 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.945911e-01 | 0.002 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.945911e-01 | 0.002 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.945911e-01 | 0.002 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.946668e-01 | 0.002 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.947977e-01 | 0.002 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.951517e-01 | 0.002 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.951759e-01 | 0.002 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.953480e-01 | 0.002 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.953480e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.953480e-01 | 0.002 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.953480e-01 | 0.002 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.953816e-01 | 0.002 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.960335e-01 | 0.002 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.960585e-01 | 0.002 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.961112e-01 | 0.002 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.961112e-01 | 0.002 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.963665e-01 | 0.002 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.967492e-01 | 0.001 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.967492e-01 | 0.001 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 9.967492e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.967981e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.968691e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.969833e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.971328e-01 | 0.001 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.971328e-01 | 0.001 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.972090e-01 | 0.001 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.972707e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.972826e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.972826e-01 | 0.001 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.972826e-01 | 0.001 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.972826e-01 | 0.001 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.972826e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.972999e-01 | 0.001 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.975560e-01 | 0.001 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.975560e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.975560e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.976056e-01 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.976673e-01 | 0.001 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.977284e-01 | 0.001 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 9.977284e-01 | 0.001 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.977284e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.979176e-01 | 0.001 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.979880e-01 | 0.001 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.980078e-01 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.980825e-01 | 0.001 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.982014e-01 | 0.001 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.984128e-01 | 0.001 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.985733e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.986533e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.987147e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.987542e-01 | 0.001 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.988910e-01 | 0.000 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.988910e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.990698e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.990832e-01 | 0.000 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.991436e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.992421e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.992568e-01 | 0.000 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.993276e-01 | 0.000 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.993523e-01 | 0.000 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.993523e-01 | 0.000 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.993725e-01 | 0.000 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.994587e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.994587e-01 | 0.000 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.995475e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.995817e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.995817e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.996162e-01 | 0.000 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.996218e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.996218e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.996307e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.996307e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.996380e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.996499e-01 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.996544e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.997028e-01 | 0.000 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.997028e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.997377e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.997577e-01 | 0.000 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.997792e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.997995e-01 | 0.000 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.998154e-01 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.998663e-01 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.998894e-01 | 0.000 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.999100e-01 | 0.000 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.999100e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.999158e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999181e-01 | 0.000 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.999205e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.999205e-01 | 0.000 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.999247e-01 | 0.000 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.999247e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.999327e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.999327e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999359e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999401e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999480e-01 | 0.000 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.999561e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.999561e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999563e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.999591e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.999604e-01 | 0.000 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.999633e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.999654e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999721e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.999744e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999748e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999790e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999808e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999830e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.999893e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.999893e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999896e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.999935e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.999939e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999943e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999943e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999944e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.999957e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999966e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999967e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999967e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.999972e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999974e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999979e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999986e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999988e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.999992e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999993e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.999994e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999995e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999995e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999999e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999999e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999999e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | -0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | -0.000 | 0 | 0 |